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Toll-like receptors (TLRs) play an important role in the innate immune system. Emerging
evidence shows that TLRs, especially endosomal TLRs, can participate in CNS diseases by
increasing the production of proinflammatory cytokines via recognition of microRNAs (miRNAs),
however which of the miRNAs are able to activate signaling and whether specific sequence
motifs are involved remains incompletely defined. Here we found that numerous miRNAs
induced TNF-a production across multiple myeloid cell types, including microglia, and that this
effect was abolished in cells deficient of TLR7. In particular, miR-20a-5p and miR-148b-3p
preferentially stimulate cytokine secretion compared to miR-20b-5p and miR-148a-3p,
respectively, despite sharing similar sequences. Further examination of closely related miRNAs
that differed in their ability to activate TLR7 resulting in the identification of a motif
(UGCUUAU) as well as specific nucleotides (all of the uridines but surprisingly including the
cytosine as well), that were vital for secretion of cytokines through TLR7 stimulation. A minimal
10-nucleotide sequence including this motif was found to be the shortest ssRNA that was
identified to signal through TLR7. A miRNA containing this motif induced multiple proinflammatory molecules, which required the PI3K, MAPK and NF-kB signaling pathways. Wild-
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type mice that were administered miR-20a-5p (containing this motif) demonstrated increased
leukocyte migration. This effect was significantly ameliorated in TLR7 knockout mice, and mice
injected with miR-20b-5p (in which the motif is mutated) failed to exert this effect. Our results
provide a detailed analysis of miRNAs that activate endosomal TLR7, and identify key
nucleotide features of sequence motif recognized by TLR7.
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LIST OF ABBREVIATIONS
miRNA micro-ribonucleic acid
TLR toll-like receptor
CNS central nervous system
TNF-a tumor necrosis factor alpha
PI3K phosphoinositide 3-kinase
MAPK mitogen-activated protein kinase
NF-kB nuclear factor kappa-light-chain-enhancer of activated B cells
PAMP pathogen-associated molecule pattern
MyD88 myeloid differentiation factor 88
TRIF TIR domain-containing adaptor inducing interferon-b
IL-1b interleukin 1 beta
ssRNA single strand ribonucleic acid
EV extracellular vesicle; also known as exosome
AD alzheimer’s disease
DOTAP N-[1-(2,3-Dioleoyloxy) propyl]-N, N, N-trimethylammonium chloride
IL-6 interleukin 6
ELISA enzyme-linked immunosorbent assay
WT wild-type
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KO knockout
MLK-3 mixed-lineage protein kinase 3
URMC-099 3-(1H-indol-5-yl)-5-[4-[(4-methyl-1-piperazinyl) methyl] phenyl]-1Hpyrrolo[2,3-b] pyridine
BMS-345541 4(2'-aminoethyl) amino-1,8-dimethylimidazo(1,2-a) quinoxaline
PCR polymerase chain reaction
CXCL10 c-x-c motif chemokine 10
PTSG-2 prostaglandin-endoperoxide synthase 2
CCL5 chemokine (c-c motif) ligand 5
GAPDH glyceraldehyde 3-phosphate dehydrogenase
Ly-6C lymphocyte antigen 6C
Ly-6G lymphocyte antigen 6G
CD11b cluster of differentiation molecule 11b
MHC class II major histocompatibility complex class II
CD170 cluster of differentiation molecule 170
LPM large peritoneal macrophage
SPM small peritoneal macrophage
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Chapter 1. Introduction
1.1 Toll-like receptors, miRNAs and Extracellular Vesicles
1.1.1 Toll-like receptors
Toll-like receptors (TLRs), an important family of pattern recognition receptors (PRRs), classically recognize conserved pathogen-associated molecular patterns (PAMPs) from infectious
pathogens. This recognition triggers the production of large amounts of proinflammatory cytokines (such as IL-1b and TNF-a), chemokines, and antiviral proteins through the activation of
interferon regulatory factor (IRF) 3, myeloid differentiation factor 88 (MyD88), TIR domaincontaining adaptor inducing interferon- b (TRIF), activator protein-1 (AP-1), and nuclear factorkappa B (NF-kB) (1-5). This family of receptors is named after the Toll gene, which was first described in Drosophila melanogaster as being important in development, and then found to be
essential in immunity (6). Since then, 13 members of the TLR family have been identified in
mice and 11 in human (7). Studies on Toll and TLRs have led to Nobel prizes in Medicine in 1995
and 2011. TLRs are located on the cell surface, in endosomes, lysosome compartments as wells
as in the endoplasmic reticulum, where they bind to their ligands. Several mechanisms are responsible for the regulation of the TLR-signaling pathways. These include conformational changes, phosphorylation, ubiquitylation, and proteasome-mediated degradation involving various
regulatory molecules (2,8,9). TLRs recognize distinct PAMPs from pathogenic organisms, such
PAMPs include lipids, lipopeptides, proteins, and nucleic acids. While such molecules in general
are specific to non-self organisms, it has been found that self-mitochondrial DNA (which evolutionarily likely originated from a symbiotic organism) can be recognized by TLR9, which recognizes certain unmethylated CpG DNA sequences, and that certain microRNAs (miRNAs) can be
recognized by TLR7 and TLR8, which recognize certain single strand RNA (ssRNA) sequences.
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Since then, miRNAs have received considerable attention as a newly identified family of regulators involved in fine-tuning of the TLR-signaling pathways. While these TLRs are present in
throughout mammals, in mice TLR8 is non-functional for signaling in response to ssRNA (10,11).

1.1.2 MiRNAs – biogenesis and maturation
MiRNAs are small noncoding ssRNAs (about 20 - 22 nucleotides in length) that are largely
studied for their binding to the 3-untranslated regions (UTRs) of target messenger RNAs
(mRNAs). This binding regulates their expression post-transcriptionally, causing mRNA degradation or protein translation repression (12,13). Canonical miRNAs are derived from endogenous precursors called primary miRNAs (pri-miRNAs), which are transcribed by RNA Polymerase II and cleaved by RNase III Drosha/DGCR8 complex. The pri-miRNAs constitute miRNA precursor (pre-miRNA) and is transported into the cellular cytoplasm. In the cytoplasm, cleavage
of the pre-miRNAs takes place once they have been loaded onto the Dicer-TRBP (TAR-RNA
binding protein) complex, which removes the loop from the pre-miRNAs to produce dsRNA
complex that contains both the mature miRNA and the so-called passenger strand. Within this
complex, the passenger strand is removed by DICER-TRBP complex resulting in a single stranded mature miRNA, which functions by being partially complementary to 3’-UTRs of target
mRNA (14,15). Aberrant expression or function of miRNAs have been identified under various
physiological and pathological conditions, e.g., in neurodegeneration and in neuroinflammation conditions (16,17).

1.1.3 Extracellular Vesicles as miRNA carriers in brain
While miRNA activities have been well characterized within their producing cells, and thus
affecting the eventual translation of gene products, miRNAs can be transported out of the cell
type of origin and carry their cargo to affect other cells in a paracrine or endocrine fashion.
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This is best documented via Extracellular Vesicles (EVs), small vesicles (between 30 and 100 nm)
released by cells with an endosome-derived membrane. EVs contain cell type-specific loads of
proteins, mRNAs and miRNAs (18). EVs can be taken up by cells and release their loads, such as
miRNAs, into cellular compartments (19,20). Transportation of miRNAs are thus secured in EVs
while the biological function of miRNAs can be retained.
In the central nervous system (CNS), neurons, astrocytes, oligodendrocytes, microglia can
release EVs into the extracellular environment (21-24); outside of the CNS a wide variety of
cells can also release EVs. One of the best studied cargoes of EVs are miRNAs (18). Interestingly a novel role for EV miRNA was found in a study on cancer, where certain miRNAs released
from cancer cells were found to bind to, and activate, mouse TLR7 as well as human TLR8 (25).
This has been similarly found in a number of systems and our lab has found EVs from brains of
monkeys with SIVE to carry miRNAs that can activate TLR7 (26). Although one other study reported that free extracellular miRNA let-7b can activate mouse TLR7 signaling in microglial
cells, the mechanism by which free miRNAs can enter brain cells and reach the endosomes to
induce signaling however, remains unclear (27). It is suggested that internalization of EVs by
target cells must precede before binding of EVs to the cell surface. The components of EVs can
thus be released into the extracellular environment. By complexing miRNAs with cationic liposomes (such as DOTAP, lipofectamine or LyoVec) and exposing the conjugates to cells, miRNAs
have been found to enter cells and locate in the endosomes in close proximity to TLR7/8, thus
mimicking the effects of natural EVs. This effect has been best documented in cells of the myeloid lineage. For example in macrophages, miR-21 and miR-29a (complexed with DOTAP) have
been shown to signal through mouse TLR7 and human TLR8 to induce TNF-a and IL-6 production (25), whereas miR-142 and miR-146a (complexed with lipofectamine) were found to signal
through mouse TLR7, leading in turn, to MIP-2, TNF-a and IL-6 production (28). Intriguingly, in
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human macrophages non-miRNAs such as HIV-1 encoded ssRNA (complexed with LyoVec)
have been shown to signal through TLR8, with subsequent release of TNF-a (29,30), thus likely
representing the traditional function of TLRs as pathogen receptors, which may have been coopted by miRNAs in EVs.

1.2 TLR7 signaling pathways mediated by miRNAs
TLR7 is type I glycoprotein expressed within endosomal compartments in a variety of innate immune cells. Its extracellular domain consists of a leader signal sequence, which directly
interact with TLR7 ligands. Endosomal and lysosomal TLRs (TLR3, 7, 8 and 9) recognize nucleic
acids and are endoplasmic reticulum (ER)-resident, and move to endosomes/lysosomes upon
ligand stimulation (31). Many signaling proteins, molecules and transcription factors are also
recruited during TLR7 activation. Endosomal/lysosomal TLRs respond to DNA/RNA derived
from pathogens and dead cells. For example, ssRNA and dsDNA directly bind to endosomal
TLR3, 7 and 9. Furthermore, TLR7 binds to miRNAs. In innate immune cells, miRNA binding to
TLR7, cellular colocalization/trafficking of TLR7, and TLR7-associated downstream signaling
cascade can together play critical roles and trigger the activation of TLR7. The precise mechanism of action of TLR7 is still unclear.

1.2.1 Direct binding of endosomal TLRs by miRNAs
Previous studies have shown that endosomal and lysosomal ssRNAs are ligand of TLR7
(10,11). Structural studies of TLR7 indicates that TLR7 interacts with guanosine and the triribonucleotide UUU (32). It is also hypothesized that the dimerization of the extracellular domain of TLRs is the triggering mechanisms of TLRs activation by ssRNA. TLR7 and TLR8 are located in the endosomal components of cells and recognize ssRNA, including miRNAs of certain
sequences (29,30,33-35). Lehmann et al. found that let-7b can act as a potent activator of TLR7
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signaling in neurons and that this activation can induce neurodegeneration (27). Previous
works from our lab and others show that miR-21 can bind to TLR7 and is neurotoxic
(13,25,26,36). Specific sequences, such as GU-rich elements or the number of U ribonucletoides, were previously described to be important for innate immune activation via ssRNAs
(10,11). Fabbri et al. suggested that GU-content as well the tridimensional structure of the
miRNAs may affect miRNA ability to functionally activate TLR7 (36). Lehmann et al. postulated
that let-7b can act as a signaling activator of TLR7 because the let-7b sequence contains a core
GU-rich motif that is also present in the HIV ssRNA40, which is a known ligand of TLR7 (27).
GUUG for miR-21 and GGUU for miR-29a is essential for the miRNA-TLR7 recognition
(13,25,26,36). Feng et al. found that miRNA mimics (miR-133a, -146a, and -208a) induced cytokine production and the effects of these miRNAs were diminished by Uridine to Adenosine
mutation (28). However, it is still unknown about consensus sequences needed to activate
TLR7. It is also important to note that miRNA binding to TLR7 alone cannot trigger the activation of TLR7. A previous study performed by Iavarone et al. indicates that although wild-type
TLR7 and TLR7rsq (mutated TLR7) bind similarly to ssRNA, mutated TLR7 is not functional and
fails to activate JNK, p38 and NF-kb. Other than the ability of TLR7 to bind to its ligands such as
ssRNA, features that are critically linked to downstream signal transduction and TLR7 trafficking are also crucial to TLR7 activation (37).

1.2.2 Cellular localization and trafficking of TLR7
Endosomal TLRs, such as TLR3, 7, 8 and 9, recognize nucleic acid and are reported to be localized in the ER. Subcellular compartmentalization and cellular trafficking of these endosomal
TLRs seem to be also crucial for ligand recognition and downstream signaling cascades (Fig 1.1).
Upon cellular stimulation or infection, TLR7 transcription is induced in the nucleus via NF-kb
and synthesized in the ER. TLR7 then exits the ER and translocate to the Golgi by uncoordinat-
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ed 93 homolog B1 (UNC93B1). In the Golgi, UNC93B1 ubiquitinates TLR7 and HRS/ESCRT machinery sorts ubiquitinated TLR7 for endosomal-lysosomal- transport. Adaptor proteins such as
AP-4 and AP-3 deliver TLR7 from the Golgi to endosomes and lysosomes. Once TLR7 reaches
the endosomes, endosomal acidification occurs for proteolytic cleavage by proteases, including furin proprotein convertases (PC). TLR7 cleavage separates the N-terminal ectodomain
from the C-terminal ectodomain, transmembrane domain, and cytosolic region. The N terminal region forms disulfide bonds with the C-terminal region and remains in the endosome for
optimal signaling (31). Kensuke et al. also suggests that TLR7 in steady-state plasmacytoid
Dendritic cells is localized in perinuclear lysosomes. Upon activation by ssRNA, TLR7 activates
two signaling pathways. One induces pro-inflammatory cytokines. The other signal activates a
small GTPase Arl8b to link TLR7-containing lysosomes with microtubules and moves them to
the peripheral region (38) for secretion of IFNs. Overall, TLR trafficking as a potential mechanism linking TLR7 activation and inflammation cascade remains to be investigated.

1.2.3 MiRNA-dependent regulation of TLR7-associated signaling proteins/molecules
and transcription factors
Although miRNAs can directly bind to TLR7, TLR7-associated downstream signaling cascade
is also critical for activation of TLR7. Lavarone et al. reported that although wild-type TLR7 and
TLR7rsq (mutated TLR7) bind similarly to ssRNA, downstream JNK, p38 and NF-kb cannot be
activated by ssRNA in mutated TLR7 . Activation of TLR7 causes recruitment of many types of
signaling proteins and molecules. These proteins and molecules include adaptor molecules
MyD88, TRIF, TRIF-related adaptor molecule (TRAM); kinases and transcription factors such as
MAP kinases, IKK1/2, NF-kB and STAT3 (Table 1.1). However, in addition to directly stimulating
TLR7, many miRNAs, by their more traditional roles of interacting with specific mRNAs, have
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been shown to affect TLR7 signaling. These miRNAs include several (miR-155, miR-21 and miR29a) that are known to be ligands for TLR7 activation and downstream effects (26,27,39).
One such miRNA is miR-155, which can target several signaling molecules as shown in Table 1.1. MiR-155 can regulate TAB2 in human monocyte-derived dendrocytes (40) as well as
MyD88 (41). MyD88 is an important adaptor molecule used by almost all TLRs except TLR3 to
activate the transcription factor NF-kB. Similarly, miR-21 can also target MyD88 as well as
IRAK1 (42). In addition, it was demonstrated that miR-155 can directly control the level of
TAB2, an important signal transduction molecule and down-regulates inflammatory cytokine
production in response to stimuli (40). Mi-155 also targets the Fas-associated death domain
protein (FADD), IkappaB kinase epsilon (IKKepsilon), and the receptor (TNFR superfamily)interacting serine-threonine kinase 1 (Ripk1) while enhancing TNF-alpha translation (40).
The tumor necrosis factor receptor (TNFR)-associated factor 4 (TRAF4) is a member of
TRAF family proteins that act as major signal transducers of the TNF receptor and the interleukin-1 receptor/Toll-like receptor (IL-1R/TLR) superfamily. TRAF4 has been reported to be overexpressed in various human cancers. TRAF4 was upregulated when cells were transfected with
inhibitor of miR-29a, implying miR-29a regulation of the TRAF4 mRNA (43).
Transcription factors, such as NF-kB, MAPK and STAT, are also activated following TLR7 activation. NF-kB is one of the most important transcription factors in TLR-dependent inflammation signaling and causes production of cytokines such as IL-6 and TNF-a. It has been shown
that miR-21, which we and others have found to be an activating ligand for TLR7, can directly
target mRNAs resulting in enhancement of the NF-kB pathway (44). Interestingly, it is also
shown that let-7 represses the activation of NF-kB (44). MiRNAs can also target other TLRactivated transcription factors. For example, miR-20a-5p and miR-17-5p can target STAT3 in
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myeloid-derived suppressor cells and alleviate the suppressive function of myeloid-derived
suppressor cells (45).
In addition to miR-155 targeting the signaling molecules such as TAB2 and MyD88 as described above, it also targets transcription factors including NF-kB, MAPK and FOXP3 (40,46).
Among these, FOXP3 is a transcription factor that is essential for the normal development of
regulatory T cells. The relationship to miR-155 was definitely shown in knockout mice in which,
in the absence of miR-155, Foxp3(+) Tregs develop but failed to maintain immune homeostasis,
leading to a scurfy-like disease (46). In summary, miRNAs can directly target expression of various signaling molecules as well as transcription factors. However, it remains to be investigated
whether and what signaling molecules and transcription factors are involved in TLR7dependent signaling by miRNAs.

1.2.4 MiRNA-dependent regulation of TLR7-associated cytokines and chemokines
Activation of TLR7 signaling leads to the transcriptional activation of genes encoding for
proinflammatory cytokines and chemokines. These cytokines and chemokines play important
roles in eradicating pathogens and recruiting inflammatory cells to the infection site for effective host defense. Several key TLR7-associated cytokines and chemokines such as IL-1b, IFN-b,
TNF-a, IL-6, CCL-5, PTSG-2 and CXCL-10 have been demonstrated to be regulated by miRNAs
(Table 1.1). For example, previous studies in our lab shows that the expression of IFN-b as well
as IFN-induced chemokine CXCL10 are decreased in miR-155 knockout mice after brain injury
(47). Transfection experiments also show marked increases of TNF-a, IL-1b and IL-6 in macrophages transfected with miR-125b or let-7b inhibitor (48). A variety of effects have been found
in vivo and in vitro regarding miRNAs and cytokines.
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Cytokines or chemokines are regulated by miRNAs by several mechanisms. First, miRNAs
can directly bind to the target 3’-UTR regions with subsequent regulation of mRNA. It has long
been known that miRNAs play important biological roles in cells through classic posttranscriptional regulation of target mRNAs. For example, let-7b can directly regulate the expression of IFN-b by targeting the IFN-b 3’-UTR (47,48). In addition, bioinformatics analysis
indicates that the 3’-UTR of the IL-6 mRNA contains a let-7-binding site (49). Let-7b inhibitor
can increase the IL-6 production in macrophages (50), however, it remains to be experimentally determined whether let-7b can suppress IL-6 directly. It has been demonstrated that miR146a is involved in negatively regulating PTGS2 expression in human gastric epithelial cells, and
miR-146a can decrease PTGS2 expression by degradation of its mRNA (47). TNF mRNA contains
a binding site that can be targeted by miR-125b in mouse RAW 264.7 macrophages (51).
Next, production of cytokines and chemokines can also be indirectly controlled by miRNAs.
Stability of proteins is crucial for their biological functions. Increasing evidences indicate that
miRNAs, together with RNA-binding proteins, regulate cytokine mRNA stability and (or) translation through the AU-rich elements (AREs) of their 3’-UTR regions. ARE-binding proteins such
as tristetraprolin (TTP), AU-rich binding factor1 (AUF1) and members of the Hu protein R (HUR)
family are regulated by miRNAs such as miR-146a. In addition, TNF mRNAs contain long AREs
targeted by TTP, a key factor in mRNA destabilization downstream of the TLR-signaling pathway (52). These finding indicate that AREs can indirectly regulate the production of cytokines
by miRNAs.
Last but not least, miRNA binding to endosomal TLR7 can trigger the inflammation cascade
and thus indirectly regulate the production of cytokines and chemokines. Lehmann et al. found
that let-7b can act as a potent activator of TLR7 signaling in microglial cells and triggers production of TNF-a (27). Fabbri et al. reported that miR-21, miR-29a and miR-147 induce TLR7
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activation and secretion of TNF-a as well as IL-6 (25,36). The excessive production of type I
IFNs is a hallmark and a main mechanism of many autoimmune diseases such as systemic lupus erythematosus. The sustained production of type I IFNs is dependent on the improper activation of plasmacytoid DCs. Savli et al. showed that synthetic miR-574 activates human
plasmacytoid DCs to secrete IFN-a via TLR7 (53).
While cytokine or chemokine expression can be regulated directly by miRNAs binding to
the target mRNA or indirectly through AREs/TLRs, a number of cytokines can also regulate
miRNA synthesis. For instance, IL-1b and TNF-a are potent stimulators for miR-146a and miR155 induction in a variety of cell types (54). Interestingly, it has also been shown that miR-155
is required for TNF mRNA stabilization and miR-155-deficient B cells and (or) miR-155-deficient
mice fail to produce TNF-a after LPS treatment (51,55). In addition to the insights discussed
above, further studies are needed to elucidate whether other TLR7-associated cytokines and
(or) chemokines are subject to regulation by miRNAs.
In summary, miRNAs can have dual activities in terms of regulation of cytokines and
chemokines: On the one hand, they bind to proteins and guide the silencing of target genes,
and on the other hand, they act independently of regulation of expression of genes and proteins by interacting directly with endosomal TLRs such as TLR7. The interplay between the two
pathways require further investigations to assess the biological and pathological significance of
the dual roles of these miRNAs.
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Figure 1.1
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Figure 1.1. TLR7 trafficking from the endoplasmic reticulum (ER) to the endosome.
In response to pro-inflammatory cytokine signaling, TLR7 transcription is induced via nuclear
factor (NF)-kB. TLR7 protein is synthesized in the ER where ER-resident chaperone proteins,
gp96 and protein-associated with TLR4 (PRAT4A), are required to facilitate proper folding of
TLR7 before exiting the ER. Upon cellular stimulation (e.g. TLR7 ligand Imiquimod) or infection,
leucine-rich repeat (LRR) containing protein 59 (LRRC59) promotes uncoordinated 93 homolog
B1 (Caenorhabditis elegans) (UNC93B1)-mediated packaging of TLR7 into coat protein complex
II (COPII)-coated vesicles to exit the ER and translocate to the Golgi. In the Golgi, UNC93B1
ubiquitinates TLR7 and HRS/ESCRT machinery sorts ubiquitinated TLR7 for endolysosomal
transport. Adaptor protein AP-4 and AP-3 deliver TLR7 from the Golgi to endosomes. Once
TLR7 reaches the endosome, endosomal acidification occurs for proteolytic cleavage by proteases, including furin proprotein convertases (PC). TLR7 cleavage separates the N-terminal ectodomain from the C-terminal ectodomain, transmembrane domain, and cytosolic region. The
N terminal region forms disulfide bonds with the C-terminal region and remains in the endosome for optimal signaling (31).
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Table 1.1
Targets of miRNAs in TLR7-associated signaling pathway
Signaling molecule

miRNA

MyD88

miR-21, miR-155, let-7b

(41,42,56)

IRAK1

miR-21

(42)

TRAF4

miR-29a

(43)

IKK

miR-155

(40,51)

FADD

miR-155

(40,51)

TAB2

miR-155

(40,51)

RIPK1

miR-155

(40,51)

miRNA

Reference(s)

Transcription Factor

Reference(s)

NF-kB

miR-21, let-7

(44)

STAT3

miR-20a, miR-17

(45)

MAPK

miR-155

(40)

FOXP3

miR-155

(46)

Cytokines, Chemokines

miRNA

Reference(s)

IL-1b

miR-125b, let-7b

(50)

IFN-b

let-7b

(48,57)

TNF-a

miR-125b, miR-146a, let-7b

(27,50,51)

IL-6

miR-125b, let-7b

(50)

CCL-5

miR-21, miR-200c

(58,59)

PTSG-2

miR-146a, miR-21

(47,60)

CXCL-10

miR-155

(61)
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1.3 Interplay Between EVs, miRNAs and TLR7 in neurodegenerative diseases
Neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD),
amyotrophic lateral sclerosis (ALS) are characterized by neuronal cell losses. Neurodegenerative diseases cause progressive degeneration and death of nerve cells, which further leads to
movement disorders such as ataxias, or dementias. Dementias are responsible for the greatest
burden of neurodegenerative diseases, with Alzheimer’s representing approximately 70% of
dementia cases. Despite significant research efforts, the primary causes of neurodegenerative
diseases remain mostly unknown.
Most of the neurodegenerative diseases and their pathological alterations, including AD,
PD, ALS and Huntington’s disease, have been associated with miRNAs. This suggests that miRNAs may be one of the contributing factors in neurodegenerative diseases and maybe used as
diagnostic biomarkers or for therapeutic purposes. It has been previously reported that miRNA
expression levels are altered in the blood of AD, PD and ALS patients. Studies have been conducted in order to utilize miRNAs for early diagnosis and treatments (62), but these have yet to
be definitive.
In Alzheimer’s disease research, Liu et al. reported that overexpression of miR-193b could
suppress the expression of amyloid precursor protein (APP). APP is the precursor molecule
whose proteolysis generates beta amyloid (Aβ), a polypeptide containing 37 to 49 amino acid
residues, whose amyloid fibrillar form is the primary component of amyloid plaques found in
the brains of Alzheimer's disease patients. This shows that miR-193b may get involved in the
neurodegenerative process, and therefore miR-193b has the potential to be a unique biomarker for AD (63). In Parkinson's disease (PD) research by Gui et al., microRNA profiling
strategy for exosomal miRNAs isolated from CSF was suggested to serve for differential diag-
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nosis of PD with AD. The purpose of exosomal miRNA biomarker researches is to be able predict future cognitive decline in asymptomatic individuals and the progression of the disease in
patients with early dementia.
Neuroinflammation can be observed during progression of neurodegenerative diseases
and involves brain cells such as microglia, oligodendrocytes, astrocytes, neuronal cells, as well
as macrophages crossing the brain-blood barrier, which can be damaged in the inflamed brain
(64). Much of this appears to involve the innate immune system, within which TLRs are important components. Whereas brief neuroinflammatory responses are considered to be neuroprotective and may even contribute neuronal development; when such responses persist
they result in neurodegeneration (65-69). Among the known TLRs so far, TLR7 can be activated
by miRNAs and result in neuro-inflammation (27). It is still unknown whether neuroinflammation in the CNS leads to the progress of neurodegenerative diseases. However, increasing evidence indicate the participation of TLR7-dependent pathways in neurodegenerative diseases. Lehmann et al have reported that TLR7 recognize GU-rich miRNAs as ligands in
the CNS (27). For example, miRNA let-7b, which is highly expressed in both microglia and neuronal cells, interacts with TLR7 to regulate transcription factors, such as MyD88, induced by
TLR7. Therefore, it is inferred that let-7b binds to miRNA-sensing TLR7 and consequently induces neurodegeneration through neuronal TLR7 (27). Our lab has shown that EVs isolated
from the brains of monkeys with SIV induced CNS disease activates TLR7 and were neurotoxic
when compared to EVs from control animals (26). Coleman et. al found that ethanol induced
TLR7 and let-7b expression, caused TLR7-associated neuroimmune gene induction and initiated the release of let-7b in EVs, enhancing TLR7-mediated neurotoxicity (70).
In summary, endogenous miRNAs may serve important functions as ligands of TLR7promotion of neuroinflammation. In addition to miRNAs, it is important to note that roles for
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EVs in transporting pathogenic proteins such as alpha-synuclein (a-syn) and amyloid precursor
protein (APP) in PD and AD, respectively, have been proposed (20,71,72). Additional information on the roles of miRNA and other pathogenic aspects of neurodegenerative disorders is
presented next.

1.3.1 Alzheimer’s Disease
AD is a chronic neurodegenerative disease that usually starts slowly and worsens over time.
It is the most common cause of dementia in the world (73). AD has been identified as a protein
misfolding disease, caused by plaque accumulation of abnormally folded amyloid beta protein
(Ab), and tau protein in the brain (74). Plaques are made up of small peptides, 39-43 amino
acids in length, called amyloid beta (Ab). Ab is a fragment from the larger amyloid precursor
protein (APP). APP is a transmembrane protein that penetrates through the neuron's membrane and is critical to neuron growth, survival, and post-injury repair (75,76). In AD, the APP is
proteolytically processed by the beta- and gamma-secretases to release the Ab peptide that is
neurotoxic and aggregates in the brain (77). AD is also considered a tauopathy due to abnormal aggregation of the tau protein. Every neuron has a cytoskeleton, an internal support structure partly made up of structures called microtubules. These microtubules act like tracks, guiding nutrients from the body of the cell to the ends of the axon and back. The tau protein stabilizes the microtubules via phosphorylation and is therefore called a microtubule-associated
protein. In AD, the tau protein is hyperphosphorylated and pairs with other threads, creating
neurofibrillary tangles and disintegrating the neuron's transport system (78).
Ab clearance is crucial to progress of AD and microglial cells are activated during removal
of these amyloid deposits (79). Activated microglia can clear the Ab deposits by phagocytic
activity pro-inflammatory cytokines However, microglia activation is often insufficient to re-
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move amyloid deposits from the aged brain and may even causes damages to neighboring cells
(80,81). In AD, activation of microglia involves endosomal TLRs such as TLR9, and boost the
clearance of Ab deposits in the brain (82). Tahara et al. reported that activation of BV-2 cells
with TLR9 ligands markedly increased ingestion of Ab . Li et al. on the other side, reported that
activation of TLR3, TLR4, TLR7, but not TLR9, reduced primary microglial CD36 transcription
and cell surface CD36 protein and reduced Aβ phagocytosis as well (83). The role of TLRs, especially endosomal TLRs, is still debated and further studies need to be conducted.
Recent studies have revealed that the catabolism of APP occurs in endosome. Ab peptides
can be secreted from the cells in association with exosomes. Exosomal proteins were found to
accumulate in the plaques of AD patient brains, suggesting a role in the pathogenesis of AD
(59). The EVs associated with Ab can be internalized into microglia and transported to microglial lysosomes, where it is degraded. Thus, neuronal EVs, which can trap Ab, act as couriers of
Ab for Ab clearance. In co-cultures of human APP-transfected N2a cells and BV2 cells, promotion of EV generation in N2a by knockdown of sphingomyelin synthase increases engulfment of
extracellular Ab by BV2 and decreases the levels of Ab in the culture medium. Infusion of neuronal EVs into APP transgenic mice decreases Ab levels and attenuates Ab toxicity in the hippocampus (84). These studies indicate that Ab clearance is EV-dependent and improvement of
Ab clearance by EV infusion may provide a novel therapeutic approach for AD.
It is also likely that miRNAs, especially exosomal miRNAs, play vital roles in the progression
of AD. Previously studies using blood samples from AD patients have identified more than 60
miRNAs up- or down-regulated in these patients in comparison with healthy individuals (85,86).
The miRNAs bind to complementary sites within the 3’-UTR region of target genes that determine the expression of APP and beta-site APP-cleaving enzyme (BACE) (87,88). Extracellular
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Ab deposits, which ultimately lead to progressive loss of neurons, are derived from processing
of APP by BACE. Significantly dysregulated miRNAs targeting APP like miR-193b (63), miR-101
(89), miR-155 (90) or BACE1 like miR-29c (87,88), miR-9 (91), miR-124 (92), miR-15b (93), miR124 (94) influence Aβ ingestion in AD brain. Furthermore, miR-193b has been shown to be present in the hippocampus of AD mice and overexpression of miR-193b could suppress the expression of APP (63). The levels of miRNA let-7 are also enhanced in AD patients (27). Lehmann
et al. reported that let-7 activates endosomal TLR7, and thus, induces neurodegeneration in
these patients.

1.3.2 Parkinson’s Disease
Parkinson’s Disease (PD) is a progressive nervous system disorder that affects movements
and is characterized by degeneration of dopaminergic neurons in the substantia nigra pars
compacta (SNpc). Symptoms start gradually, sometimes starting with a barely noticeable
tremor in one hand. The disorder also commonly causes stiffness, bradykinesia and postural
instability (95). The main pathological characteristics of PD are the presence of intracellular
inclusion termed Lewy bodies (accumulations of the fibrillar alpha-synuclein) in the neurons
and cell death in the basal ganglia. The loss of neurons is accompanied by the death of astrocytes as well as increase of microglial cells in the substantia nigra (96).
In PD and other Lewy body disorders, the main pathology has been accredited to the accumulation of alpha-synuclein. There are a number of proposed mechanisms by which alphasynuclein results in neurodegeneration, some of which involve the innate immune system. For
example the accumulation of alpha-synuclein activates microglia, increasing dopaminergic
neurotoxicity (97,98).
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Although initially alpha-synuclein was considered a purely intracellular protein, accumulating evidences from recent studies suggests that alpha-synuclein can spread readily between
cells (99,100). It has also been shown that such cell-to-cell transfer can occur as neuron-toneuron, glial cell-to-glial cell as well as neuron-to-microglia (101,102). Although the precise
molecular mechanisms are not fully understood, cell-to-cell transfer of alpha synuclein via EVs
has been reported. Alpha-synuclein is present in EVs from cultured cells and secreted via a calcium-dependent mechanism (103). When inhibiting lysosomal action in alpha-synuclein overexpressing neural cell lines, EV secretion of alpha-synuclein increased and promoted cell-tocell transfer of alpha-synuclein (103,104). Furthermore, cell-derived EVs containing alphasynuclein were found to induce cell death in neuronal cell lines (103).
The human studies have identified a large number of dysregulated microRNAs in PD brain
tissue samples (72). The profile of miRNA dysregulation differs among various regions of the
PD brains: Included among those having upregulated expression are: miR-199b, -544a, -488, 221, -144 (cingulate gyri); miR-221-3p, -95 (putamen); miR-21, -224, -373, -26b, -106a, -301b
(substantia nigra); miR-224, -373 (amygdala); miR-200b, -200a, -195, -424 (frontal cortex); miR16-5p (prefrontal cortex). Those with downregulated expression are: miR-7, -145 (cingulate
gyri); miR-155-5p, -34b (putamen); miR-198, -485-5p, -339-5p, -208b, -135b, -299-5p, -330-5p,
-542-3p, -379, -337-5p, -34b, -34c (substantia nigra); miR-34b, -34c (amygdala); miR- 200a, 199a-3p, -148a, -451, -144, -429, -190, -34b, -34c -205 (frontal cortex); let-7i-3p, miR-184, 127-5p (prefrontal cortex).
Downstream target gens of several miRNAs have also been identified in the previous PD
studies, and alterations of these miRNAs can greatly affect the pathology and progression of
PD. By and large, PD has not been considered to be a genetic disease and the majority of cases
are idiopathic. However, leucine-rich repeat kinase2 (LRRK2) is one of the greatest known ge-
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netic contributors to PD, and mutations of LRRK2 account for 15 to 20 percent of PD cases in
the Ashkenazi Jewish, and about 40 percent of cases in the North African Arab Berbers. It has
been demonstrated that the levels of let-7 are correlated with the expression of alphasynuclein and LRRK2, coded by the two main genes associated with PD (105). A recent report
has also indicated that let-7 represses the expression of alpha-synuclein and is downregulated
in PD models (106). LRRK2 is also an experimentally validated target of miR-1224, which is
downregulated in PD (71). The miRNAs also target the 3’-UTR regions of targeted genes and
proteins. For example, upregulated miR-21 in PD can directly target the 3’-UTR of lysosomeassociated membrane protein 2A (LAMP2A) (107); Downregulated miR-135a-5p targets the 3’UTR of rho-associated protein kinase2 (ROCK2) and plays a role in the protective effects of hydrogen sulfide against PD (108).
Increasing evidences suggest a close relationship between PD and TLRs. It has been recently shown that extracellular alpha-synuclein induces BV-2 microglial cells activation and secrete
proinflammatory mediators such as TNF-a and IL-1b (109). In addition, the expression of TLR1,
TLR7, MyD88, NF-kB, TNF-a and IL-1b are increased while the expression of TLR4, TLR6, TLR9
and CD36 are decreased or unchanged (109). These findings indicate that alpha-synuclein can
activate microglia through TLR7. However, further studies need to be conducted in order to
show that TLR7 can mediate cell death in mouse model of Parkinson disease (such as MPTP
model).
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Chapter 2. MATERIAL AND METHODS
Oligonucleotides
MiRNAs with phosphorothioate or phosphodiester linkages were synthesized, desalted, and
purified by reverse-phase cartridge by Sigma-Aldrich (St. Louis, MO, USA). MiRNAs were used
by complexing with (or where specified without) DOTAP reagent (Sigma-Aldrich).

Cells
RAW 264.7 macrophages (American Type Culture Collection, Manassus, VA, USA) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen, CA, USA) supplemented
with 10% fetal bovine serum (FBS) (Invitrogen) and penicillin-streptomycin. N1E-115 neuroblast cells (American Type Culture Collection) were cultured in DMEM with 4.5 g/L glucose
without sodium pyruvate (Invitrogen) supplemented with 10% FBS. SH-SY5Y neuroblastoma
cells were obtained from American Type Culture Collection and grown in Dulbecco’s modified
eagle’s medium/Nutrient mixture F-12 (DMEM/F12) (Invitrogen) with 10% FBS supplemented
with L-glutamine. BV-2 immortalized microglial cells (American Type Culture Collection) were
grown and routinely maintained in DMEM with 10% FBS and incubated at 37° C and 5% CO2.
The NR-9460 microglial cell line, derived from wild-type mice (denoted WT microglia), and the
NR-19980 microglial cell line, derived from TLR7 knockout mice (denoted TLR7ko microglia)
(BEI Resources, Manassus, VA, USA), were cultured in DMEM supplemented with 10% FBS, 2
mM L-glutamine, 1 mM sodium pyruvate and 10 μg/ml ciprofloxacin. Cells were grown to confluence at 37° C in humidified air with 5% CO2.

AlamarBlue Assay for cellular survival/viability
Responsiveness of N1E-115 cell to miRNAs was determined by alamarBlue assay. The active
ingredient of alamarBlue (resazurin) is a nontoxic, cell permeable compound that is blue in
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color and virtually nonfluorescent. Upon entering cells, resazurin is reduced and produces red
fluorescence. Nonviable cells have no metabolic capacity and will not reduce the dye. 1.25 x
104 cells were plated in 96-well plates and were incubated for the indicated times with let-7b3p (Sigma-Aldrich) complexed (or not) to the transfection agent DOTAP (Sigma-Aldrich), using
various ratios of miRNAs to DOTAP. After incubation with alamarBlue (Invitrogen) for 4 h at
room temperature, the absorbance was read at 570 nm using a microplate reader according to
the manufacturer’s recommendations.

Isolation of SH-SY5Y-derived Extracellular Vesicles
EVs were isolated from SH-SY5Y neuroblastoma cells as previously described, with minor modifications (110,111). Confluent SH-SY5Y cells were washed with 1X phosphor-buffered saline
(PBS) (Invitrogen) and then grown in DMEM/F12 without phenol red supplemented with exosome-depleted FBS (System Biosciences, Palo Alto, CA, USA) to avoid potential disturbance of
the following assay with Nanosight (112).Culture supernatants were centrifuged at 300 g for
20 minutes at room temperature to remove cell debris and large particles. The resultant supernatants were ultracentrifuged at 150,000 at 4° C for 1 hour. The resulting pellets were
washed and resuspended with 1X PBS.

TNF-a and IL-6 ELISA
Cells were incubated for the indicated times with the indicated concentrations of miRNAs
complexed to the transfection agent DOTAP (Sigma-Aldrich), using a ratio of miRNAs to DOTAP
of 1:6. Conditioned medium was collected and analyzed by mouse TNF-a or IL-6 ELISA kit from
eBioscience (San Diego, CA, USA), with lower limit of detection of 8 pg/ml and upper limit of
linearity of 1000 pg/ml (8pg/ml, 500 pg/ml for IL-6 assay). For each determination technical
duplicates were averaged. The number of biological replicates is given in each figure legend.
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Final cytokine concentrations were calculated based on a standard curve constructed in each
independent experiment. Values <8 and >1000 pg/ml were recorded as 8 and 1000 pg/ml, respectively (8 and 500 pg/ml for IL-6 assay).

Inhibitors of signal transduction pathways
Microglial cells were pre-treated with 100 nM MLK-3 inhibitor URMC-099 (Cayman Chemical,
Ann Arbor MI, USA), 1 µM PI3K inhibitor Wortmannin (Sigma-Aldrich) or 10 µM IKK inhibitor
BMS-345541 (Sigma-Aldrich) for 30 minutes prior to miRNA-DOTAP stimulation.

RNA extraction and analysis
To prepare total RNA from cultured microglial cell lines, cells were plated at the density of 1.5 x
106 cells/well in 6-well plates. Cells were then subjected to RNA extraction using Trizol reagent
according to the manufacturer’s instructions (Invitrogen). Two micrograms of total RNA from
cultured cells was used for subsequent cDNA synthesis. A real-time PCR assay was performed
using the AppliedBiosystems StepOnePlus Real-Time PCR system. Primers and probes were purchased premade stocks from AppliedBioSysystems (Pleasanton, CA, USA), for the following
genes: TNF- a (Mm00443258_m1), IL-6 (Mm00446190_m1), CXCL10 (Mm00445235_m1), PTSG2 (Mm00478374_m1), IL-1 b (Mm00433228_m1) and CCL5(Mm01302427_m1). Relative levels
were determined by the ddCt method, using GAPDH (Mm99999915_g1) as the housekeeping
control. Each PCR was run as a technical duplicate and averaged, the number of biological replicates is given in the figure legend.

Animals
Wild-type (WT, C57BL/6) and TLR7ko mice were purchased from Jackson Laboratories (Bar
Harbor, Maine, USA) and bred in the University of Nebraska Medical Center animal facility. The
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animal protocols were approved by the Institutional Animal Care and Use Committee of the
University of Nebraska Medical Center, and followed National Institutes of Health guidelines.

Culture and proliferation of primary bone marrow-derived macrophages
Immortalized primary bone marrow-derived macrophages (BMDMs) were generated from
mice femurs as previously described (113) and cultured in RPMI-1649 supplemented with 10%
FBS, penicillin-streptomycin and M-CSF. Cells were plated in 96-wells culture plates at 250,000
cells per well for future transfections.

Primary mouse microglial cell isolation
Primary microglia cells were obtained from 1- to 3-day-old C57BL/6 newborn pups and isolated
as previously described. After removal of brains, the cortices were dissected and digested in
Hanks buffered salt solution (Invitrogen) containing 0.25% trypsin (Invitrogen). Mixed glial cultures were then prepared by re-suspending the cell suspension in DMEM containing 10% heatinactivated FBS, 100 U/ml penicillin, and 0.1 mg/ml streptomycin. Cells were plated at a density of 5 × 106 cells/flask in 75 cm2 cell culture flasks. Cell medium was replaced every 5 days,
and after the first medium change, 0.25 ng/ml macrophage colony stimulating factor (Invitrogen) was added to the flasks to promote microglial proliferation. Upon reaching confluence (7
to 10 days), cultures were shaken at 37° C at 220 rpm for 2 h to detach microglia from the flask
surface. The cell medium, containing the released microglia cells, was collected and centrifuged at 1000xg for 5 min to collect the pelleted cells, which were then plated on 96-well tissue culture plates at 25,000 cells/well for all subsequent experiments.
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In vivo miRNA treatment
WT and TLR7 knockout mice (8-12 weeks of age) were treated with 20 µg miRNA-mimics complexed with DOTAP, negative control (DOTAP only) or saline. Animals were injected intraperitoneally and 20 hours post-injection, under light isoflurane anesthesia, mice were sacrificed by
cervical dislocation and their abdomen opened for the collection of intraperitoneal fluid. The
peritoneal cavity was flushed with 5 ml PBS with 3% FBS, and gently massaged before removing the fluid containing intraperitoneal leukocytes. The fluid was centrifuged to pellet cells,
resuspended in sterile PBS, counted and used for flow cytometric analysis. Each experiment
consisted of one mouse of each genotype, and five biological replicates were performed.

Flow Cytometry
Isolated intraperitoneal cells were washed with PBS and stained for live/dead assay (L23105,
Invitrogen). Live/dead reagent was removed by centrifugation and cells were blocked for 5 min
with rat CD16/CD32 Fc Block (BD Biosciences) and then stained with fluorescently labeled antibodies: anti-mouse Ly-6C (HK1.4), Ly-6G (1A8), CD11b (M1/70), MHC class II (M5/114.15.2),
CD170 (IRNM44N), F4/80 (bm8) (eBioscience), for 45 minutes on ice. After washing and fixing,
data were acquired on an LSRFortessa (Becton Dickinson, Franklin Lakes, NJ, USA) in the University of Nebraska Medical Center Flow Cytometry core facility, and analyzed using BD
FACSDiva software version 6.2, Firmware version 1.12 (Becton Dickinson) or Flowjo 6.0 (Flowjo,
LLC). Due to inconsistent staining the CD170 (used in order to identify eosinophils) results
were not used in the analysis.

Statistics
Statistics were performed using Prism 7.0 (GraphPad Software, La Jolla, CA, USA). For the in
vitro studies one-way ANOVA was followed by Dunnett’s multiple comparison test to the con-
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trol condition, for the in vivo studies two-way ANOVA was followed by Sidak’s post-hoc test
with the p value adjusted for multiple comparisons. Alpha was set to 0.05 for significance.
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Chapter 3. Activation of TLR7 by miRNAs in brain cells
3.1 Rationale
In the present study we hypothesized that many miRNAs can activate endosomal TLR7 of
brain innate immune cells, such as macrophages and microglia. We investigated the toxicity of
our transfection complex and utilized various brain cells. Based on a comprehensive screen of
of cytokine production via activation of microglialTLR7 by miRNAs, the study was conducted to
explore the role of miRNAs in the brain and to identify potential pathogenic pathways in neurodegenerative diseases.

3.2 Results
3.2.1 MiRNA-DOTAP complex does not affect the viability of N1E-115 cells
In order to test the effect of the miRNA-DOTAP complex on cell viability and to determine
the optimal ratio of miRNA to DOTAP to be used, we chose to assess the absorbance of alamarBlue after incubation of N1E-115 cells with various ratios of miRNA to DOTAP for indicated
time (Fig. 3.1). MiRNA-DOTAP complex does not affect the viability of cells and appears to
have little cytotoxicity.
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Figure 3.1
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Figure 3.1. miRNA-DOTAP complex does not affect the viability of N1E-115 neuroblast cells.
N1E-115 neuroblast cells were treated with or without let-7b complexed to DOTAP at indicated ratios, let-7b-3p alone, DOTAP alone or Triton for A) 24 hours, B) 48 hours or C) 72 hours
followed by alamarBlue assays. The results are presented as mean ± SEM. ***p < 0001 when
compared to the untreated. n=3 for all experiments. MiRNA-DOTAP complex is not toxic to
cells.
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3.2.2 MiRNAs activate RAW 264.7 cells in a dose-dependent manner
The macrophage population of the CNS include the microglia, perivascular macrophages,
meningeal macrophages, macrophage of the circumventricular organs and the macrophages of
the choroid plexus. We first investigated the response of TLR7 expressing RAW 264.7 macrophages to indicated miRNAs based on previously published literatures (26,27,114,115). It
should be noted that RAW 264.7 macrophages also contain may other PAMPs including TLRs
such as TLR4, which is activated by pathogens like LPS (116), thus this is not specific for TLR7
but enabled a screen of whether a large number of miRNAs could activate PAMPs. Following
incubation with various doses of indicated miRNAs complexed to transfection agent DOTAP for
16 hours, TNF-a levels in the culture supernatants were measured by ELISA. At 2 µg/ml, miR21, miR-9 and let-7i caused release of more than 800 pg/ml TNF-a release. Let-7b only caused
release of less than 200 pg/ml TNF-a (Fig 3.2).
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Figure 3.2
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Figure 3.2. Synthetic miRNAs stimulate RAW 264.7 macrophages to release TNF-alpha in a
dose-dependent manner.
RAW 264.7 cells were incubated for 16 hours with various doses of miRNAs. Subsequently,
TNF-a amounts in the culture supernatants were determined by ELISA. Imiquimod (5 µg/ml)
was used as a positive control and caused more than 1000 pg/ml TNF-a release (data not
shown).
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Table 3.1
miRNA

Sequence

RAW 264.7 cells
TNF-a (mean ± SEM)

let-7a-5p

5'-UGAGGUAGUAGGUUGUAUAGUU-3'

38.3 ± 0.4

let-7b-5p

5'-UGAGGUAGUAGGUUGUGUGGUU-3'

224.3 ± 10.5

let-7c-5p

5'-UGAGGUAGUAGGUUGUAUGGUU-3'

143.1 ± 7.9

let-7d-5p

5'-AGAGGUAGUAGGUUGCAUAGUU-3'

28.9 ± 0.8

let-7e-5p

5'-UGAGGUAGGAGGUUGUAUAGUU-3'

392.4 ± 29

let-7f-5p

5'-UGAGGUAGUAGAUUGUAUAGUU-3'

76.2 ± 3

let-7g-5p

5'-UGAGGUAGUAGUUUGUACAGUU-3'

313.5 ± 21.8

let-7i-5p

5'-UGAGGUAGUAGUUUGUGCUGUU-3'

high

miR-100-5p

5'-AACCCGUAGAUCCGAACUUGUG-3'

high

miR-101a-3p

5'-UACAGUACUGUGAUAACUGAA-3'

miR-103-3p

5'-AGCAGCAUUGUACAGGGCUAUGA-3'

miR-106b-5p

5'-UAAAGUGCUGACAGUGCAGAU-3'

miR-107-3p

5'-AGCAGCAUUGUACAGGGCUAUCA-3'

high

miR-10a-5p

5'-UACCCUGUAGAUCCGAAUUUGUG-3'

high

miR-10b-5p

5'-UACCCUGUAGAACCGAAUUUGUG-3'

high

miR-122-5p

5'-UGGAGUGUGACAAUGGUGUUUG-3'

high

miR-124-3p

5'-UAAGGCACGCGGUGAAUGCC-3'

miR-125a-5p

5'-UCCCUGAGACCCUUUAACCUGUGA-3'

high

miR-125b-5p

5'-UCCCUGAGACCCUAACUUGUGA-3'

high

miR-126a-3p

5'-UCGUACCGUGAGUAAUAAUGCG-3'

30.7 ± 1.3

miR-126a-5p

5'-CAUUAUUACUUUUGGUACGCG-3'

960.6 ± 58.3

miR-128-3p

5'-UCACAGUGAACCGGUCUCUUU-3'

347.1 ± 19.3

miR-129-5p

5'-CUUUUUGCGGUCUGGGCUUGC-3'

653.8 ± 12.6

miR-130a-3p

5'-CAGUGCAAUGUUAAAAGGGCAU-3'

122.3 ± 2.7

miR-130b-3p

5'-CAGUGCAAUGAUGAAAGGGCAU-3'

31 ± 1.2

miR-132-3p

5'-UAACAGUCUACAGCCAUGGUCG-3'

147.4 ± 8.7

miR-133a-3p

5'-UUUGGUCCCCUUCAACCAGCUG-3'

509.1 ± 21.4

miR-133b-3p

5'-UUUGGUCCCCUUCAACCAGCUA-3'

489.3 ± 48.7

miR-134-5p

5'-UGUGACUGGUUGACCAGAGGGG-3'

miR-135a-5p

5'-UAUGGCUUUUUAUUCCUAUGUGA-3'

high

miR-135b-5p

5'-UAUGGCUUUUCAUUCCUAUGUGA-3'

high

28.9 ± 1.7
290.2 ± 30.9
38.1 ± 1

25.9 ± 0.1

33.2 ± 1.4
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miR-137-3p

5'-UUAUUGCUUAAGAAUACGCGUAG-3'

212.5 ± 6

miR-138-5p

5'-AGCUGGUGUUGUGAAUCAGGCCG-3'

30.6 ± 1.3

miR-140-3p

5'-UACCACAGGGUAGAACCACGG-3'

287 ± 14.9

miR-140-5p

5'-CAGUGGUUUUACCCUAUGGUAG-3'

high

miR-141-3p

5'-UAACACUGUCUGGUAAAGAUGG-3'

182.1 ± 2.3

miR-142a-3p

5'-UGUAGUGUUUCCUACUUUAUGGA-3'

miR-142a-5p

5'-CAUAAAGUAGAAAGCACUACU-3'

miR-143-3p

5'-UGAGAUGAAGCACUGUAGCUC-3'

miR-144-3p

5'-UACAGUAUAGAUGAUGUACU-3'

miR-145a-5p

5'-GUCCAGUUUUCCCAGGAAUCCCU-3'

miR-146a-5p

5'-UGAGAACUGAAUUCCAUGGGUU-3'

high

miR-146b-5p

5'-UGAGAACUGAAUUCCAUAGGCU-3'

high

miR-147-3p

5'-GUGUGCGGAAAUGCUUCUGCUA-3'

high

miR-148a-3p

5'-UCAGUGCACUACAGAACUUUGU-3'

763.5 ± 57.2

miR-148b-3p

5'-UCAGUGCAUCACAGAACUUUGU-3'

high

miR-149-5p

5'-UCUGGCUCCGUGUCUUCACUCCC-3'

high

miR-150-5p

5'-UCUCCCAACCCUUGUACCAGUG-3'

high

miR-152-3p

5'-UCAGUGCAUGACAGAACUUGG-3'

miR-15a-5p

5'-UAGCAGCACAUAAUGGUUUGUG-3'

high

miR-15b-5p

5'-UAGCAGCACAUCAUGGUUUACA-3'

662.5 ± 3.8

miR-16-5p

5'-UAGCAGCACGUAAAUAUUGGCG-3'

28.7 ± 0.5

miR-17-5p

5'-CAAAGUGCUUACAGUGCAGGUAG-3'

86.7 ± 1.5

miR-181a-1-3p

5'-ACCAUCGACCGUUGAUUGUACC-3'

miR-181a-5p

5'-AACAUUCAACGCUGUCGGUGAGU-3'

345.2 ± 2.9

miR-181b-5p

5'-AACAUUCAUUGCUGUCGGUGGGU-3'

158.2 ± 10

miR-181c-5p

5'-AACAUUCAACCUGUCGGUGAGU-3'

miR-181d-5p

5'-AACAUUCAUUGUUGUCGGUGGGU-3'

miR-183-5p

5'-UAUGGCACUGGUAGAAUUCACU-3'

833.6 ± 6.9

miR-184-3p

5'-UGGACGGAGAACUGAUAAGGGU-3'

24.7 ± 0.5

miR-185-5p

5'-UGGAGAGAAAGGCAGUUCCUGA-3'

380 ± 5.3

miR-186-5p

5'-CAAAGAAUUCUCCUUUUGGGCU-3'

101.2 ± 0.6

miR-187-3p

5'-UCGUGUCUUGUGUUGCAGCCGG-3'

miR-18a-5p

5'-UAAGGUGCAUCUAGUGCAGAUAG-3'

40.1 ± 0.2

miR-191-5p

5'-CAACGGAAUCCCAAAAGCAGCUG-3'

49.9 ± 0.2

755.9 ± 43.4
32.4 ± 1.3
404.2 ± 14.2
88.7 ± 1.8
133.9 ± 3.1

913.6 ± 48.1

766.2 ± 30.9

high
861.1 ± 28.8

high
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miR-192-5p

5'-CUGACCUAUGAAUUGACAGCC-3'

150.4 ± 3.3

miR-193a-3p

5'-AACUGGCCUACAAAGUCCCAGU-3'

25.2 ± 0.3

miR-194-5p

5'-UGUAACAGCAACUCCAUGUGGA-3'

74.5 ± 0.9

miR-195a-5p

5'-UAGCAGCACAGAAAUAUUGGC-3'

34.4 ± 0.5

miR-196a-5p

5'-UAGGUAGUUUCAUGUUGUUGGG-3'

high

miR-196b-5p

5'-UAGGUAGUUUCCUGUUGUUGGG-3'

741.2 ± 22.9

miR-199a-5p

5'-CCCAGUGUUCAGACUACCUGUUC-3'

high

miR-19a-3p

5'-UGUGCAAAUCUAUGCAAAACUGA-3'

58.2 ± 3.4

miR-19b-3p

5'-UGUGCAAAUCCAUGCAAAACUGA-3'

49.3 ± 1.8

miR-1a-3p

5'-UGGAAUGUAAAGAAGUAUGUAU-3'

96.6 ± 5.8

miR-200a-3p

5'-UAACACUGUCUGGUAACGAUGU-3'

59.9 ± 2.6

miR-200b-3p

5'-UAAUACUGCCUGGUAAUGAUGA-3'

57 ± 3.3

miR-200c-3p

5'-UAAUACUGCCGGGUAAUGAUGGA-3'

miR-203-3p

5'-GUGAAAUGUUUAGGACCACUAG-3'

368.6 ± 43.3

miR-204-5p

5'-UUCCCUUUGUCAUCCUAUGCCU-3'

high

miR-205-5p

5'-UCCUUCAUUCCACCGGAGUCUG-3'

369.2 ± 4

miR-206-3p

5'-UGGAAUGUAAGGAAGUGUGUGG-3'

26.5 ± 0.3

miR-20a-5p

5'-UAAAGUGCUUAUAGUGCAGGUAG-3'

high

miR-20b-5p

5'-CAAAGUGCUCAUAGUGCAGGUAG-3'

415.5 ± 12.9

miR-210-3p

5'-CUGUGCGUGUGACAGCGGCUGA-3'

43.3 ± 1.2

miR-214-3p

5'-ACAGCAGGCACAGACAGGCAGU-3'

25.8 ± 0.6

miR-218-5p

5'-UUGUGCUUGAUCUAACCAUGU-3'

miR-21a-5p

5'-UAGCUUAUCAGACUGAUGUUGA-3'

high

miR-22-3p

5'-AAGCUGCCAGUUGAAGAACUGU-3'

111.8 ± 11.8

miR-221-3p

5'-AGCUACAUUGUCUGCUGGGUUUC-3'

99.5 ± 9.2

miR-222-3p

5'-AGCUACAUCUGGCUACUGGGU-3'

29.1 ± 0.7

miR-223-3p

5'-UGUCAGUUUGUCAAAUACCCCA-3'

high

miR-23a-3p

5'-AUCACAUUGCCAGGGAUUUCC-3'

high

miR-23b-3p

5'-AUCACAUUGCCAGGGAUUACC-3'

403.8 ± 41.8

miR-24-3p

5'-UGGCUCAGUUCAGCAGGAACAG-3'

928.3 ± 19.3

miR-25-3p

5'-CAUUGCACUUGUCUCGGUCUGA-3'

high

miR-26a-5p

5'-UUCAAGUAAUCCAGGAUAGGCU-3'

385.5 ± 34.5

miR-26b-5p

5'-UUCAAGUAAUUCAGGAUAGGU-3'

191.5 ± 13.7

miR-27a-3p

5'-UUCACAGUGGCUAAGUUCCGC-3'

high

22.9 ± 0.2

997.7 ± 14.2
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miR-27b-3p

5'-UUCACAGUGGCUAAGUUCUGC-3'

high

miR-28a-5p

5'-AAGGAGCUCACAGUCUAUUGAG-3'

43.3 ± 0.7

miR-296-5p

5'-AGGGCCCCCCCUCAAUCCUGU-3'

23.3 ± 0.1

miR-29a-3p

5'-UAGCACCAUCUGAAAUCGGUUA-3'

miR-29b-3p

5'-UAGCACCAUUUGAAAUCAGUGUU-3'

miR-29c-3p

5'-UAGCACCAUUUGAAAUCGGUUA-3'

miR-301a-3p

5'-CAGUGCAAUAGUAUUGUCAAAGC-3'

high

miR-302d-3p

5'-UAAGUGCUUCCAUGUUUGAGUGU-3'

high

miR-30a-5p

5'-UGUAAACAUCCUCGACUGGAAG-3'

43.6 ± 0.3

miR-30b-5p

5'-UGUAAACAUCCUACACUCAGCU-3'

49.3 ± 1.2

miR-30c-5p

5'-UGUAAACAUCCUACACUCUCAGC-3'

miR-30d-5p

5'-UGUAAACAUCCCCGACUGGAAG-3'

64.9 ± 4.1

miR-30e-5p

5'-UGUAAACAUCCUUGACUGGAAG-3'

152.3 ± 14.3

miR-32-5p

5'-UAUUGCACAUUACUAAGUUGCA-3'

163.2 ± 0.3

miR-320-3p

5'-AAAAGCUGGGUUGAGAGGGCGA-3'

66.4 ± 3.6

miR-328-3p

5'-CUGGCCCUCUCUGCCCUUCCGU-3'

328.2 ± 88.9

miR-33-5p

5'-GUGCAUUGUAGUUGCAUUGCA-3'

511.3 ± 12.1

miR-335-5p

5'-UCAAGAGCAAUAACGAAAAAUGU-3'

63.8 ± 0.6

miR-338-3p

5'-UCCAGCAUCAGUGAUUUUGUUG-3'

high

miR-339-5p

5'-UCCCUGUCCUCCAGGAGCUCACG-3'

114.5 ± 21

miR-342-3p

5'-UCUCACACAGAAAUCGCACCCGU-3'

82.1 ± 5.3

miR-34a-5p

5'-UGGCAGUGUCUUAGCUGGUUGU-3'

high

miR-34c-5p

5'-AGGCAGUGUAGUUAGCUGAUUGC-3'

miR-375-3p

5'-UUUGUUCGUUCGGCUCGCGUGA-3'

miR-381-3p

5'-UAUACAAGGGCAAGCUCUCUGU-3'

672.8 ± 42.9

miR-409-3p

5'-GAAUGUUGCUCGGUGAACCCCU-3'

298.3 ± 70.7

miR-411-5p

5'-UAGUAGACCGUAUAGCGUACG-3'

miR-423-5p

5'-UGAGGGGCAGAGAGCGAGACUUU-3'

82.3 ± 8.9

miR-425-5p

5'-AAUGACACGAUCACUCCCGUUGA-3'

86.9 ± 1.8

miR-431-5p

5'-UGUCUUGCAGGCCGUCAUGCA-3'

miR-433-3p

5'-AUCAUGAUGGGCUCCUCGGUGU-3'

646.8 ± 19.2

miR-451a

5'-AAACCGUUACCAUUACUGAGUU-3'

118.2 ± 8.4

miR-455-5p

5'-UAUGUGCCUUUGGACUACAUCG-3'

430 ± 0.6

miR-484

5'-UCAGGCUCAGUCCCCUCCCGAU-3'

85.6 ± 1.2

high
261.9 ± 7
827.1 ± 0.2

54 ± 2.4

967.5 ± 13
high

90 ± 3.5

169.2 ± 9.9
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miR-485-5p

5'-AGAGGCUGGCCGUGAUGAAUUC-3'

157.3 ± 2.7

miR-499-5p

5'-UUAAGACUUGCAGUGAUGUUU-3'

miR-574-3p

5'-CACGCUCAUGCACACACCCACA-3'

69.2 ± 0.9

miR-652-3p

5'-AAUGGCGCCACUAGGGUUGUG-3'

71.1 ± 2.4

miR-744-5p

5'-UGCGGGGCUAGGGCUAACAGCA-3'

66.4 ± 0.7

miR-7a-5p

5'-UGGAAGACUAGUGAUUUUGUUGU-3'

61.4 ± 0.9

miR-9-3p

5'-AUAAAGCUAGAUAACCGAAAGU-3'

miR-9-5p

5'-UCUUUGGUUAUCUAGCUGUAUGA-3'

high

miR-93-5p

5'-CAAAGUGCUGUUCGUGCAGGUAG-3'

high

miR-96-5p

5'-UUUGGCACUAGCACAUUUUUGCU-3'

966.6 ± 26.3

miR-98-5p

5'-UGAGGUAGUAAGUUGUAUUGUU-3'

458.9 ± 25.3

miR-99a-5p

5'-AACCCGUAGAUCCGAUCUUGUG-3'

high

high

117.4 ± 4.1
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Table 3.1 Names, sequences, and TNF-a release when miRNA:DOTAP complex was used to
stimulate RAW 264.7 cells.
Values indicate TNF-a levels (pg/ml) in the culture supernatant 16 hours after addition of
miRNA:DOTAP complex, average of technical duplicates and standard error of the mean are
reported. High: values above the linear range of detection of the assay 1000 pg/ml.
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3.2.3 Numerous miRNAs cause TNF-a release in RAW 264.7 cells
We extended the study and investigated the response of RAW 264.7 monocytemacrophage cell line to a series of commonly studied miRNAs (Table 3.1). Sixteen hours after
stimulation with indicated miRNAs complexed to DOTAP (1 to 6 ratio), conditioned medium
was collected and analysed for TNF-a release. A wide range of miRNAs were found capable of
producing TNF-a inRAW 264.7 cells. For values below or above the linear range of detection of
the assay (8 pg/ml and 1000 pg/ml, respectively) values of 8 or 1000 are reported. Many of the
miRNAs elicited high levels of TNF-a after transfection. 40 of the tested miRNAs led to production of TNF-a at or above the detection level of the assay (1000 pg/ml). Another 57 of the
miRNAs elicited the release of 100 to 1000 pg/ml of TNF-a. Again it must be pointed out that
RAW macrophages express not only TLR7, but also other PAMPs. Thus the effect of activation
may be due to PAMP including other TLRs instead of TLR7 alone (116). This study provides initial sight of the ability of miRNAs activating the TLRs.

3.2.4 Validation of miRNA-induced TNF-a release in N1E-115 and SH-SY5Y cells
In order to further validate the miRNA induced TNF-a in RAW 264.7 cells, indicated miRNAs
were combined with DOTAP and incubated with N1E-115 cells and SH-SY5Y cells. Although
miR-21, miR-15a and let-7b have been previously reported to be biological relevant and induced significant amount of TNF-a in RAW 264.7 cells, they did not cause increased production of TNF-a in N1E-115 or SH-SY5Y cells (Fig 3.3 & 3.4).
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Figure 3.3
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Figure 3.3. Validation of miRNA-induced TNF-a release in N1E-115 cells.
N1E-115 cells were incubated for 16 hours or 48 hours with 6 µg/ml of indicated miRNAs. Subsequently, relative absorbance of TNF-a in the culture supernatants were determined by ELISA.
Results are presented as mean ± SEM, n=3. Tested miRNAs did not induce release TNF-a release in N1E-115 cells.
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Figure 3.4
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Figure 3.4. Validation of miRNA-induced TNF-a release in SH-SY5Y cells.
SH-SY5Y cells were incubated for 16 hours with 6 µg/ml of indicated miRNAs. Subsequently,
the amount of TNF-a in the culture supernatants were determined by ELISA. Results are presented as mean ± SEM, n=2. Tested miRNAs did not induce release TNF-a release in SH-SY5Y
cells.
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3.2.5 MiRNAs induce the release of TNF-a from immortalized wild-type or TLR7 knock
out bone marrow derived macrophages (BMDM).
To confirm the specificity of TLR7-activation via miRNAs, BMDMs from wild type and TLR7
deficient mice were then tested with miRNAs that induced significant amount of TNF-a in RAW
264.7 cells (Table 3.1). BMDMs were isolated and then incubated with indicated miRNAs. Subsequently, TNF-a release in the culture supernatants was determined by ELISA. As shown in
Table 3.2, incubation with miR-21 and miR-15a stimulated TNF-a release (34.4 pg/ml and 15.1
pg/ml). All miRNAs did not cause release of TNF-a in TLR7 knock out BMDMs. However, let-7
family miRNAs still did not show any stimulation of TNF-a release while miR-138 produced
TNF-a of over 120 pg/ml.

50
Table 3.2

miRNA

WT BMDM

TLR7ko BMDM

miR-149

147.7

8.0

miR-138

121.3

8.0

miR-93

112.5

8.0

miR-146b

80.6

8.0

miR-135b

65.4

8.0

miR-146a

58.4

8.0

miR-302d

45.3

8.0

miR-233

45.0

8.0

miR-21

34.4

8.0

miR-375

34.4

8.0

miR-27a

22.7

8.0

miR-10a

21.0

8.0

miR-23a

19.1

8.0

miR-196b

17.8

8.0

miR-15a

15.1

8.0

miR-196a

11.3

8.0

miR-24

11.0

8.0

miR-199a

10.8

8.0

let-7i

9.5

8.0

miR-147b

9.5

8.0

miR-20a

9.2

8.0

miR-181d

8.6

8.0

miR-133b

8.0

8.0

miR-204

8.0

8.0

miR-15b

8.0

8.0

miR-125b

8.0

8.0

miR-218

8.0

8.0

miR-99a

8.0

8.0

miR-135a

8.0

8.0
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miR-142a

8.0

8.0

miR-181a-13

8.0

8.0

miR-20b

8.0

8.0

miR-133a

8.0

8.0

miR-107

8.0

8.0

miR-98

8.0

8.0

miR-122

8.0

8.0

miR-124

8.0

8.0

miR-143

8.0

8.0

miR-499

8.0

8.0

miR-187

8.0

8.0

miR-150

8.0

8.0

miR-338

8.0

8.0

miR-100

8.0

8.0

miR-301a

8.0

8.0

miR-9

8.0

8.0

let-7b

8.0

8.0

miR-25

8.0

8.0

miR-27b

8.0

8.0

miR-29a

8.0

8.0

miR-34a

8.0

8.0

miR-124

8.0

8.0

miR-10b

8.0

8.0

miR-148

8.0

8.0

miR-181c

8.0

8.0

miR-125a

8.0

8.0

miR-34c

8.0

8.0

miR-96

8.0

8.0

miR-126a

8.0

8.0

miR-152

8.0

8.0

miR-183

8.0

8.0
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miR-29c

8.0

8.0

miR-148a

8.0

8.0

miR-381

8.0

8.0

miR-129

8.0

8.0

miR-433

8.0

8.0

miR-33

8.0

8.0

miR-455

8.0

8.0
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Table 3.2 Names and TNF-a release when 10 µg/ml of miRNA:DOTAP complex was used to
stimulate the WT or TLR7ko BMDMs.
Primary BMDMs from WT and TLR7ko mice were cultured in 96-wells culture plates. Average
value of 3 duplicates indicating TNF-a amounts (pg/ml) in the culture supernatant 16 hours
after addition of 10 µg/ml of miRNA:DOTAP complex is reported. For values below the linear
range of detection of the assay (8 pg/ml) values of 8 are reported.
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3.2.6 MiRNAs induce the release of TNF-a and IL-6 in wild-type but not in TLR7 knock
out microglial cells.
Microglial cells are the resident macrophages-like cells of the CNS with a broad role in the
brain’s innate immunity and inflammatory processes. In order to ensure that the effects seen
by miRNAs are not just in macrophages and are TLR7-dependent, we utilized microglial cell
lines derived from wild-type or TLR7 knock out mice. In the wild-type microglia, tested miRNAs
(miR-93 and miR-25) were capable of inducing TNF-a production at various doses (Fig 3.5). In
order to further assess the role microglial TLR7 in this stimulation induced by miRNAs, we extended our study via testing 145 miRNAs. In the wild-type microglia, many of the tested miRNAs were found to elicit TNF-a or IL-6 production (Table 3.3 & 3.4). In the TLR7ko microglia on
the other hand, the stimulation effects were almost completed abolished (Table 3.3 & 3.4).

3.2.7 let-7b-5p does not induce TNF-a production in BV-2 microglia or primary mouse
microglia.
Let-7 family miRNAs contains a GU-rich core motif in proximal to 3’ end. Previous studies
have shown the stimulation effects of let-7 family miRNAs, in particular let-7b (27). We were
puzzled by our results with the let-7 family miRNAs in macrophages and microglial cells (Table
3.1, 3.2, 3.3). Only let-7i-tp induced TNF-a in RAW 264.7 macrophages and wild-type microglia
in our experiments. We thus tested let-7b-5p in both the BV-2 microglial cells as well as the
primary mouse microglia. Based on our previous data from RAW 264.7 cells and wild-type microglia, a potent and poor miRNA inducer of TNF-a (miR-20a-5p and miR-17-5p, respectively)
were also tested. Let-7b-5p failed to induce TNF-a in BV-2 microglia or primary mouse microglia (Fig 3.6).
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3.2.8 Modification of let-7 family miRNAs does not induce TNF-a production in wildtype mouse microglia.
While we utilized oligonucleotides with phosphodiester linkages, it has been reported that
free (not complexed with DOTAP or other transfection molecules) let-7b could signal through
TLR7. In addition, many studies use phosphorothioate linkages to make the oligonucleotides
resistant to RNase. We thus treated the wild-type microglia with newer preparations of let-7b5p (as well as two other strong miRNA inducer of TNF-a) containing phosphodiester or phophorothioate linkages, as well as with phosphodiester linkages but in the absence of DOTAP.
Under these treatments, let-7b-5p was still incapable of inducing TNF-a (Fig 3.7).
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Figure 3.5
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Figure 3.5 Various doses of miRNAs induce the release of TNF-a in wild-type microglial cells.
Wild-type mice microglial cells were incubated with indicated doses of miRNAs for 16, 24 or 40
hours. Culture supernatants were collected and assesses by TNF-a ELISA. Data represent results of technical duplicates.
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Table 3.3
miRNA

Sequence

WT

TLR ko

let-7a-5p

5'-UGAGGUAGUAGGUUGUAUAGUU-3'

33.08

n.d.

let-7b-5p

5'-UGAGGUAGUAGGUUGUGUGGUU-3'

n.d.

n.d.

let-7c-5p

5'-UGAGGUAGUAGGUUGUAUGGUU-3'

n.d.

n.d.

let-7d-5p

5'-AGAGGUAGUAGGUUGCAUAGUU-3'

n.d.

n.d.

let-7e-5p

5'-UGAGGUAGGAGGUUGUAUAGUU-3'

n.d.

n.d.

let-7f-5p

5'-UGAGGUAGUAGAUUGUAUAGUU-3'

0.61

n.d.

let-7g-5p

5'-UGAGGUAGUAGUUUGUACAGUU-3'

2.75

n.d.

let-7i-5p

5'-UGAGGUAGUAGUUUGUGCUGUU-3'

320.74

n.d.

miR-100-5p

5'-AACCCGUAGAUCCGAACUUGUG-3'

459.51

n.d.

miR-101a-3p

5'-UACAGUACUGUGAUAACUGAA-3'

n.d.

n.d.

miR-103-3p

5'-AGCAGCAUUGUACAGGGCUAUGA-3'

12.31

n.d.

miR-106b-5p

5'-UAAAGUGCUGACAGUGCAGAU-3'

n.d.

n.d.

miR-107-3p

5'-AGCAGCAUUGUACAGGGCUAUCA-3'

48.94

n.d.

miR-10a-5p

5'-UACCCUGUAGAUCCGAAUUUGUG-3'

225.40

n.d.

miR-10b-5p

5'-UACCCUGUAGAACCGAAUUUGUG-3'

129.36

n.d.

miR-122-5p

5'-UGGAGUGUGACAAUGGUGUUUG-3'

155.80

n.d.

miR-124-3p

5'-UAAGGCACGCGGUGAAUGCC-3'

n.d.

n.d.

miR-125a-5p

5'-UCCCUGAGACCCUUUAACCUGUGA-3'

40.14

n.d.

miR-125b-5p

5'-UCCCUGAGACCCUAACUUGUGA-3'

156.70

n.d.

miR-126a-3p

5'-UCGUACCGUGAGUAAUAAUGCG-3'

n.d.

n.d.

miR-126a-5p

5'-CAUUAUUACUUUUGGUACGCG-3'

33.02

n.d.

miR-128-3p

5'-UCACAGUGAACCGGUCUCUUU-3'

n.d.

n.d.

miR-129-5p

5'-CUUUUUGCGGUCUGGGCUUGC-3'

36.85

n.d.

miR-130a-3p

5'-CAGUGCAAUGUUAAAAGGGCAU-3'

n.d.

n.d.

miR-130b-3p

5'-CAGUGCAAUGAUGAAAGGGCAU-3'

n.d.

n.d.

miR-132-3p

5'-UAACAGUCUACAGCCAUGGUCG-3'

n.d.

n.d.

miR-133a-3p

5'-UUUGGUCCCCUUCAACCAGCUG-3'

72.28

n.d.

miR-133b-3p

5'-UUUGGUCCCCUUCAACCAGCUA-3'

72.51

n.d.

miR-134-5p

5'-UGUGACUGGUUGACCAGAGGGG-3'

n.d.

n.d.

miR-135a-5p

5'-UAUGGCUUUUUAUUCCUAUGUGA-3'

206.44

n.d.
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miR-135b-5p

5'-UAUGGCUUUUCAUUCCUAUGUGA-3'

429.45

n.d.

miR-137-3p

5'-UUAUUGCUUAAGAAUACGCGUAG-3'

n.d.

n.d.

miR-138-5p

5'-AGCUGGUGUUGUGAAUCAGGCCG-3'

87.47

n.d.

miR-140-3p

5'-UACCACAGGGUAGAACCACGG-3'

n.d.

n.d.

miR-140-5p

5'-CAGUGGUUUUACCCUAUGGUAG-3'

8.92

n.d.

miR-141-3p

5'-UAACACUGUCUGGUAAAGAUGG-3'

7.65

n.d.

miR-142a-3p

5'-UGUAGUGUUUCCUACUUUAUGGA-3'

112.65

n.d.

miR-142a-5p

5'-CAUAAAGUAGAAAGCACUACU-3'

n.d.

n.d.

miR-143-3p

5'-UGAGAUGAAGCACUGUAGCUC-3'

n.d.

n.d.

miR-144-3p

5'-UACAGUAUAGAUGAUGUACU-3'

n.d.

n.d.

miR-145a-5p

5'-GUCCAGUUUUCCCAGGAAUCCCU-3'

n.d.

n.d.

miR-146a-5p

5'-UGAGAACUGAAUUCCAUGGGUU-3'

18.00

n.d.

miR-146b-5p

5'-UGAGAACUGAAUUCCAUAGGCU-3'

22.82

n.d.

miR-147-3p

5'-GUGUGCGGAAAUGCUUCUGCUA-3'

25.59

n.d.

miR-148a-3p

5'-UCAGUGCACUACAGAACUUUGU-3'

130.63

n.d.

miR-148b-3p

5'-UCAGUGCAUCACAGAACUUUGU-3'

453.95

n.d.

miR-149-5p

5'-UCUGGCUCCGUGUCUUCACUCCC-3'

156.73

n.d.

miR-150-5p

5'-UCUCCCAACCCUUGUACCAGUG-3'

110.40

n.d.

miR-152-3p

5'-UCAGUGCAUGACAGAACUUGG-3'

294.92

n.d.

miR-15a-5p

5'-UAGCAGCACAUAAUGGUUUGUG-3'

89.11

n.d.

miR-15b-5p

5'-UAGCAGCACAUCAUGGUUUACA-3'

n.d.

n.d.

miR-16-5p

5'-UAGCAGCACGUAAAUAUUGGCG-3'

n.d.

n.d.

miR-17-5p

5'-CAAAGUGCUUACAGUGCAGGUAG-3'

30.32

n.d.

miR-181a-1-3p

5'-ACCAUCGACCGUUGAUUGUACC-3'

2.23

n.d.

miR-181a-5p

5'-AACAUUCAACGCUGUCGGUGAGU-3'

n.d.

n.d.

miR-181b-5p

5'-AACAUUCAUUGCUGUCGGUGGGU-3'

n.d.

n.d.

miR-181c-5p

5'-AACAUUCAACCUGUCGGUGAGU-3'

6.28

n.d.

miR-181d-5p

5'-AACAUUCAUUGUUGUCGGUGGGU-3'

n.d.

n.d.

miR-183-5p

5'-UAUGGCACUGGUAGAAUUCACU-3'

19.24

n.d.

miR-184-3p

5'-UGGACGGAGAACUGAUAAGGGU-3'

n.d.

n.d.

miR-185-5p

5'-UGGAGAGAAAGGCAGUUCCUGA-3'

2.33

n.d.

miR-186-5p

5'-CAAAGAAUUCUCCUUUUGGGCU-3'

n.d.

n.d.

miR-187-3p

5'-UCGUGUCUUGUGUUGCAGCCGG-3'

112.44

n.d.
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miR-18a-5p

5'-UAAGGUGCAUCUAGUGCAGAUAG-3'

n.d.

n.d.

miR-191-5p

5'-CAACGGAAUCCCAAAAGCAGCUG-3'

n.d.

n.d.

miR-192-5p

5'-CUGACCUAUGAAUUGACAGCC-3'

n.d.

n.d.

miR-193a-3p

5'-AACUGGCCUACAAAGUCCCAGU-3'

n.d.

n.d.

miR-194-5p

5'-UGUAACAGCAACUCCAUGUGGA-3'

n.d.

n.d.

miR-195a-5p

5'-UAGCAGCACAGAAAUAUUGGC-3'

n.d.

n.d.

miR-196a-5p

5'-UAGGUAGUUUCAUGUUGUUGGG-3'

85.89

n.d.

miR-196b-5p

5'-UAGGUAGUUUCCUGUUGUUGGG-3'

17.69

n.d.

miR-199a-5p

5'-CCCAGUGUUCAGACUACCUGUUC-3'

146.60

n.d.

miR-19a-3p

5'-UGUGCAAAUCUAUGCAAAACUGA-3'

n.d.

n.d.

miR-19b-3p

5'-UGUGCAAAUCCAUGCAAAACUGA-3'

n.d.

n.d.

miR-1a-3p

5'-UGGAAUGUAAAGAAGUAUGUAU-3'

5.44

n.d.

miR-200a-3p

5'-UAACACUGUCUGGUAACGAUGU-3'

n.d.

n.d.

miR-200b-3p

5'-UAAUACUGCCUGGUAAUGAUGA-3'

7.81

n.d.

miR-200c-3p

5'-UAAUACUGCCGGGUAAUGAUGGA-3'

6.91

n.d.

miR-203-3p

5'-GUGAAAUGUUUAGGACCACUAG-3'

24.83

n.d.

miR-204-5p

5'-UUCCCUUUGUCAUCCUAUGCCU-3'

78.63

n.d.

miR-205-5p

5'-UCCUUCAUUCCACCGGAGUCUG-3'

20.69

n.d.

miR-206-3p

5'-UGGAAUGUAAGGAAGUGUGUGG-3'

n.d.

n.d.

miR-20a-5p

5'-UAAAGUGCUUAUAGUGCAGGUAG-3'

438.41

n.d.

miR-20b-5p

5'-CAAAGUGCUCAUAGUGCAGGUAG-3'

75.49

n.d.

miR-210-3p

5'-CUGUGCGUGUGACAGCGGCUGA-3'

n.d.

n.d.

miR-214-3p

5'-ACAGCAGGCACAGACAGGCAGU-3'

14.91

n.d.

miR-218-5p

5'-UUGUGCUUGAUCUAACCAUGU-3'

25.59

n.d.

miR-21a-5p

5'-UAGCUUAUCAGACUGAUGUUGA-3'

102.39

n.d.

miR-22-3p

5'-AAGCUGCCAGUUGAAGAACUGU-3'

11.99

n.d.

miR-221-3p

5'-AGCUACAUUGUCUGCUGGGUUUC-3'

140.03

n.d.

miR-222-3p

5'-AGCUACAUCUGGCUACUGGGU-3'

n.d.

n.d.

miR-223-3p

5'-UGUCAGUUUGUCAAAUACCCCA-3'

118.81

n.d.

miR-23a-3p

5'-AUCACAUUGCCAGGGAUUUCC-3'

176.53

n.d.

miR-23b-3p

5'-AUCACAUUGCCAGGGAUUACC-3'

11.21

n.d.

miR-24-3p

5'-UGGCUCAGUUCAGCAGGAACAG-3'

49.22

n.d.

miR-25-3p

5'-CAUUGCACUUGUCUCGGUCUGA-3'

202.69

n.d.
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miR-26a-5p

5'-UUCAAGUAAUCCAGGAUAGGCU-3'

6.49

n.d.

miR-26b-5p

5'-UUCAAGUAAUUCAGGAUAGGU-3'

27.05

n.d.

miR-27a-3p

5'-UUCACAGUGGCUAAGUUCCGC-3'

42.58

n.d.

miR-27b-3p

5'-UUCACAGUGGCUAAGUUCUGC-3'

134.92

n.d.

miR-28a-5p

5'-AAGGAGCUCACAGUCUAUUGAG-3'

n.d.

n.d.

miR-296-5p

5'-AGGGCCCCCCCUCAAUCCUGU-3'

4.49

n.d.

miR-29a-3p

5'-UAGCACCAUCUGAAAUCGGUUA-3'

88.01

n.d.

miR-29b-3p

5'-UAGCACCAUUUGAAAUCAGUGUU-3'

14.62

n.d.

miR-29c-3p

5'-UAGCACCAUUUGAAAUCGGUUA-3'

60.64

n.d.

miR-301a-3p

5'-CAGUGCAAUAGUAUUGUCAAAGC-3'

47.58

n.d.

miR-302d-3p

5'-UAAGUGCUUCCAUGUUUGAGUGU-3'

39.26

n.d.

miR-30a-5p

5'-UGUAAACAUCCUCGACUGGAAG-3'

n.d.

n.d.

miR-30b-5p

5'-UGUAAACAUCCUACACUCAGCU-3'

11.43

n.d.

miR-30c-5p

5'-UGUAAACAUCCUACACUCUCAGC-3'

17.98

n.d.

miR-30d-5p

5'-UGUAAACAUCCCCGACUGGAAG-3'

13.14

n.d.

miR-30e-5p

5'-UGUAAACAUCCUUGACUGGAAG-3'

11.31

n.d.

miR-32-5p

5'-UAUUGCACAUUACUAAGUUGCA-3'

14.99

n.d.

miR-320-3p

5'-AAAAGCUGGGUUGAGAGGGCGA-3'

11.81

n.d.

miR-328-3p

5'-CUGGCCCUCUCUGCCCUUCCGU-3'

92.96

n.d.

miR-33-5p

5'-GUGCAUUGUAGUUGCAUUGCA-3'

31.28

n.d.

miR-335-5p

5'-UCAAGAGCAAUAACGAAAAAUGU-3'

14.36

n.d.

miR-338-3p

5'-UCCAGCAUCAGUGAUUUUGUUG-3'

455.50

n.d.

miR-339-5p

5'-UCCCUGUCCUCCAGGAGCUCACG-3'

11.17

n.d.

miR-342-3p

5'-UCUCACACAGAAAUCGCACCCGU-3'

12.34

n.d.

miR-34a-5p

5'-UGGCAGUGUCUUAGCUGGUUGU-3'

259.98

n.d.

miR-34c-5p

5'-AGGCAGUGUAGUUAGCUGAUUGC-3'

31.39

n.d.

miR-375-3p

5'-UUUGUUCGUUCGGCUCGCGUGA-3'

111.60

n.d.

miR-381-3p

5'-UAUACAAGGGCAAGCUCUCUGU-3'

27.06

n.d.

miR-409-3p

5'-GAAUGUUGCUCGGUGAACCCCU-3'

14.27

n.d.

miR-411-5p

5'-UAGUAGACCGUAUAGCGUACG-3'

15.14

n.d.

miR-423-5p

5'-UGAGGGGCAGAGAGCGAGACUUU-3'

12.08

n.d.

miR-425-5p

5'-AAUGACACGAUCACUCCCGUUGA-3'

12.84

n.d.

miR-431-5p

5'-UGUCUUGCAGGCCGUCAUGCA-3'

13.32

n.d.
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miR-433-3p

5'-AUCAUGAUGGGCUCCUCGGUGU-3'

16.37

n.d.

miR-451a

5'-AAACCGUUACCAUUACUGAGUU-3'

12.58

n.d.

miR-455-5p

5'-UAUGUGCCUUUGGACUACAUCG-3'

17.77

n.d.

miR-484

5'-UCAGGCUCAGUCCCCUCCCGAU-3'

12.61

n.d.

miR-485-5p

5'-AGAGGCUGGCCGUGAUGAAUUC-3'

24.73

n.d.

miR-499-5p

5'-UUAAGACUUGCAGUGAUGUUU-3'

52.46

n.d.

miR-574-3p

5'-CACGCUCAUGCACACACCCACA-3'

15.23

n.d.

miR-652-3p

5'-AAUGGCGCCACUAGGGUUGUG-3'

11.78

n.d.

miR-744-5p

5'-UGCGGGGCUAGGGCUAACAGCA-3'

10.81

n.d.

miR-7a-5p

5'-UGGAAGACUAGUGAUUUUGUUGU-3'

12.39

n.d.

miR-9-3p

5'-AUAAAGCUAGAUAACCGAAAGU-3'

67.42

n.d.

miR-9-5p

5'-UCUUUGGUUAUCUAGCUGUAUGA-3'

232.52

n.d.

miR-93-5p

5'-CAAAGUGCUGUUCGUGCAGGUAG-3'

438.93

n.d.

miR-96-5p

5'-UUUGGCACUAGCACAUUUUUGCU-3'

27.44

n.d.

miR-98-5p

5'-UGAGGUAGUAAGUUGUAUUGUU-3'

113.92

n.d.

miR-99a-5p

5'-AACCCGUAGAUCCGAUCUUGUG-3'

437.62

n.d.
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Table 3.3 Names, sequences, and TNF-a release when 6 µg/ml miRNA:DOTAP complex was
used to stimulate the wild-type (WT) or TLR7 knock out (TLR7ko) microglia.
Values indicate TNF-a levels (pg/ml) in the culture supernatant 16 hours after addition of 6
µg/ml miRNA:DOTAP complex, average of technical duplicates is reported.
n.d.: not detected.
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Table 3.4

miRNA

Sequence

WT

TLR7 ko

miR-10a-5p

5'- UACCCUGUAGAUCCGAAUUUGUG -3'

n.d.

n.d.

miR-10b-5p

5'- UACCCUGUAGAACCGAAUUUGUG -3'

n.d.

n.d.

miR-135a-5p

5'- UAUGGCUUUUUAUUCCUAUGUGA -3'

17

n.d.

miR-135b-5p

5'- UAUGGCUUUUCAUUCCUAUGUGA -3'

57

n.d.

miR-146a-5p

5'- UGAGAACUGAAUUCCAUGGGUU -3'

n.d.

n.d.

miR-148a-3p

5'- UCAGUGCACUACAGAACUUUGU -3'

25

n.d.

miR-148b-3p

5'- UCAGUGCAUCACAGAACUUUGU -3'

170

n.d.

miR-149-5p

5'- UCUGGCUCCGUGUCUUCACUCCC -3'

n.d.

n.d.

miR-196a-5p

5'- UAGGUAGUUUCAUGUUGUUGGG -3'

10

n.d.

miR-196b-5p

5'- UAGGUAGUUUCCUGUUGUUGGG -3'

n.d.

n.d.

miR-20a-5p

5'- UAAAGUGCUUAUAGUGCAGGUAG -3'

192

n.d.

miR-20b-5p

5'- CAAAGUGCUCAUAGUGCAGGUAG -3'

n.d.

n.d.

miR-21-5p

5'- UAGCUUAUCAGACUGAUGUUGA -3'

n.d.

n.d.

miR-23a-3p

5'- AUCACAUUGCCAGGGAUUUCC -3'

29

n.d.

miR-23b-3p

5'- AUCACAUUGCCAGGGAUUACC -3'

n.d.

n.d.

miR-27b-3p

5'- UUCACAGUGGCUAAGUUCUGC -3'

n.d.

n.d.

miR-27a-3p

5'- UUCACAGUGGCUAAGUUCCGC -3'

n.d.

n.d.

miR-29a-3p

5'- UAGCACCAUCUGAAAUCGGUUA -3'

n.d.

n.d.

miR-29b-3p

5'- UAGCACCAUUUGAAAUCAGUGUU -3'

n.d.

n.d.

miR-29c-3p

5'- UAGCACCAUUUGAAAUCGGUUA -3'

n.d.

n.d.

miR-338-3p

5'- UCCAGCAUCAGUGAUUUUGUUG -3'

92

n.d.

miR-9-5p

5'- UCUUUGGUUAUCUAGCUGUAUGA -3'

17

n.d.

miR-93-5p

5'- CAAAGUGCUGUUCGUGCAGGUAG -3'

163

n.d.

let-7a-5p

5'- UGAGGUAGUAGGUUGUAUAGUU -3'

n.d.

n.d.

let-7b-5p

5'- UGAGGUAGUAGGUUGUGUGGUU -3'

n.d.

n.d.

let-7c-5p

5'- UGAGGUAGUAGGUUGUAUGGUU -3'

n.d.

n.d.

let-7d-5p

5'- AGAGGUAGUAGGUUGCAUAGUU -3'

n.d.

n.d.

let-7e-5p

5'- UGAGGUAGGAGGUUGUAUAGUU -3'

n.d.

n.d.

let-7f-5p

5'- UGAGGUAGUAGAUUGUAUAGUU -3'

n.d.

n.d.
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let-7g-5p

5'- UGAGGUAGUAGUUUGUACAGUU -3'

n.d.

n.d.

let-7i-5p

5'- UGAGGUAGUAGUUUGUGCUGUU -3'

28

n.d.
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Table 3.4 Names, sequences, and IL-6 release when 6 µg/ml miRNA:DOTAP complex was
used to stimulate the wild-type (WT) or TLR7 knock out (TLR7ko) microglia.
Values indicate IL-6levels (pg/ml) in the culture supernatant 16 hours after addition of 6 µg/ml
miRNA:DOTAP complex, average of technical duplicates is reported.
n.d.: not detected.
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Figure 3.6
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Figure 3.6. Let-7b-5p does not induce TNF-a in BV-2 microglia or primary mouse microglia.
A) BV-2 cells, treated with 6 µg/ml miRNAs as well as positive controls (5 µg/ml Imiquimod or
1 µg/ml LPS) for 16 hours or were left untreated (cells alone). B) Primary mouse microglia from
C57BL/6 mice, treated with 10 µg/ml miRNA complexed to DOTAP, 10 µg/ml Imiquimod, 1
µg/ml LPS, or left untreated. Culture supernatants were collected and assesses by TNF-a ELISA.
Data represent results mean ± SEM. n=3 independent experiments.
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Figure 3.7
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Figure 3.7 Modification of let-7b-5p does not induce TNF-a in wild-type mouse microglia.
Wild-type microglial cells were treated with 6 µg/ml miRNAs containing phosphodiester or
phosphorothioate (PS) linkage complexed (or not) to the transfection agent DOTAP for 16
hours. Culture supernatants were collected and assesses by TNF-a ELISA. Data represent results mean ± SEM. n=3 independent experiments.
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3.3 Discussion
Our studies complement and expand upon knowledge of miRNA-TLR interactions, and
provide significant new insights. 40 of the tested miRNAs led to production of TNF-a at or
above the detection level of the assay (1000 pg/ml) in RAW 264.7 cells; Another 57 of the
miRNAs elicited the release of 100 to 1000 pg/ml of TNF-a. Transfection with synthetic miRNAs complexed with DOTAP, especially with miR-21, also stimulated TNF-a release in wild-type
BMDMs, whereas all miRNAs did not cause release of TNF-a in TLR7 knock out BMDMs. Previous work from our lab showed miR-21 was increased in EVs in traumatic brain injuries and can
also lead to neuronal cell death (26,117,118), and others miR-21 as well as let-7c to suppress
the dendritic growth of cortical neurons in a TLR7 dependent manner (34). Our works show
that miRNAs can signal through TLR7 in macrophages.
We also found a broad range of miRNAs that can signal through TLR7 in WT microglia; 59
of the 145 miRNAs initially tested led to the production of >25 pg/ml of TNF-a, and 30 of those
with levels of >100 pg/ml, whereas in TLR7ko microglia none reached the level of detection of
the assay (8 pg/ml). Furthermore, miR-20a and miR-93 led to TNF-a and IL-6 productions while
their closely related miRNAs (miR-20b and miR-17) caused no productions of TNF-a or IL-6.
Infusion of miR-20a into the uninjured spinal cord caused inflammation and neuronal cell
death similar to the pathology observed after trauma-induced Spinal Cord Injury in patients
(119).
A number of miRNAs have been previously found to signal through TLR7 in different cell
types (predominately in macrophages and microglia lineage): let-7a, -7b, -7c, -7g; and miR-21, 29a, -29b, -34a, -122, -133a, -142, -146a, -208a, -599 (25,27,28,35). Although miRNA:DOTAP
complexes caused TLR7-dependent cytokine production in macrophages and microglial cells,
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synthetic miRNAs did not induce TNF-a production in SH-SY5Y or N1E-115 cells in our experiments. We think that synthetic miRNAs may cause various effects depending on the morphology of cells. We were puzzled by the relative lack of TNF-a production following treatment
with the let-7 family members (just low amounts with let-7a, higher levels only with let-7i) in
our experiments, despite attempting to replication conditions (with and without DOTAP, and
the use of phosphorothiolate as well as phosphodiesterase linkages. It is still not clear the reason for this difference. However the others that were tested in detail (miR-21, -29a, -34a, and 122) indeed activated microglia and macrophages through TLR7.
Current therapeutic activities for neurodegenerative disorders are restricted due to the
limited understanding of their underlying mechanisms as well as the difficulties posed in accurately diagnosing. Pathological changes can initiate earlier than the appearance of clinical
symptoms. Recently, miRNA microarray, miRNA qPCR assay and especially deep-sequencing
technology has been applied for identification of differentially expresses miRNAs during the
progress of neurodegenerative diseases(120,121). Exosomal miRNA profiles from human biological fluids such as CSF and plasma have prompted the potential application of miRNAs as
diagnostic biomarkers for neurodegenerative diseases (63,122-124). However, current methods of isolation and purification of EVs via ultracentrifugation cannot achieve the goal of isolating the EVs with high-yield and may stand in the way of mass application of exosomal diagnostic biomarkers.
It is also worth noting that the free miRNAs without DOTAP complexation did not induce
TNF-a release in vitro, indicating miRNA mimics need to be enveloped in some type of carriers,
such as DOTAP, to protect them from degradation and/or enable them to efficiently reach the
endosome. Circulating miRNAs are also enveloped in some type of carriers, such as EVs. Our
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miRNA transfection complex is shown to be relatively intoxic, thus providing a physiological
method of delivering synthetic miRNAs for potential therapeutic purposes.
In summary, we screened a wide profile of miRNAs inducing TNF-a and IL-6 responses in
macrophages and microglial cells. Our studies provide further evidence that miRNAs can act as
signals for TLR7 activation. These finding correlate with dysregulation of miRNAs in CNS diseases.
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Chapter 4. Sequence-specific miRNA-induced TLR7 activation in vitro and in vivo
4.1 Introduction
In the current study, we screened a wide profile of miRNAs inducing TNF-a and IL-6 responses in macrophages and microglial cells. Our study provides further evidence that miRNAs
can act as signals for TLR7 activation. However, little is known about consensus sequences
needed to activate TLR7, although GU-content, GU-repeats, and poly-U are frequently implicated in this process (10,11,13,25,27,36). In the present study we hypothesized that several
miRNAs could activate endosomal TLR7, leading in turn, to increased production of proinflammatory molecules, and induction of inflammatory responses in vivo. We thus chose
miRNAs on the basis of their validated expression in tissues and diseases and focused on those
with sequence homology in mice and human, as well as assessed these for TLR7-specific stimulation of TNF-a release. We also examined the signaling transduction pathways used by miRNAs for transcriptional stimulation of pro-inflammatory molecules. Additionally, we also analyzed the miRNA sequence motifs that could stimulate mouse TLR7, and that were active in
vivo.

4.2.1 In-depth examination of closely related miRNAs
Our previous results have shown that miRNAs can induce TNF-a production in a TLR7dependent manner. Despite the failure of let-7b family miRNAs to induce TNF-a production,
we performed a more in-depth examination of a subset of miRNAs based on our data from
wild-type microglia (Table 3.3). We focused on several families of miRNAs containing members
sharing related sequences but divergent TNF-a responses. The TLR7 ligand Imiquimod and
TLR4 ligand LPS were used as controls (Fig 4.1B). Parallel studies in TLR7 knock out microglia
showed that none could stimulate TNF-a production (Fig 4.1B). Within the miR-20a-5p family
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and miR-148b-3p family, a range of TNF-a was produced (Fig 4.1A). These findings suggested
the existence of key motifs and/or nucleotides that could be responsible for TLR7 stimulation.
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Figure 4.1
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Figure 4.1. Closely related miRNA sequences differ in TLR7 activation.
A) Wild-type microglia were treated with indicated miRNAs, conditions as in Table 3.3. Green,
purple and red shading indicate miRNAs with closely related sequences. Results are shown as
mean ± SEM. These experiments were performed with three independent experiments. B) The
deficiency of TLR7 abolished imiquimod-induced TNF-a production in TLR7 knock out cells. The
TLR7 ligand imiquimod was used at 5 µg/ml, the TLR4 ligand LPS was used at 1 µg/ml (as a positive control in WT and TLR7ko microglia), as a negative control DOTAP was added without any
miRNA (cells+DOTAP). Results are presented as mean ± SEM. These experiments were performed with three independent experiments.
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4.2.2 Specific U → C miRNA sequence mutations and “UGCUUAU” motif deletion diminishes miRNA-induced cytokine response
It was previously hypothesized that a GU-rich element contained in miRNAs can specifically
stimulate TLR7 (27). Based on our data, miR-148b-3p caused significantly more TNF-a production in wild-type microglia than miR-148a-3p despite both having 18% G and 32% U elements
(Table 4.1, Fig 4.1). These findings indicate that GU-rich may not be the sole requirement for
TLR7 activation in microglia. Key nucleotides or sequence motifs of miRNAs may play a more
important role in microglial TLR7 activation. In order to help reveal such key nucleotides or
sequence motifs responsible for TLR7 stimulation, we used both natural occurring miRNAs
members of the miR-148 family (miR-148a-3p, miR-148b-3p) and the miR-20 family (miR-20a5p, miR-20b-5p, miR-17-5p, miR-93-5p), along with a series of their site-directed nucleotide
substitution. In all these experiments tests were performed on both Wild-type and TLR7 knock
out microglial cells in parallel. TLR7 knock out cells failed to produce TNF-a (data not shown).
We found that miR-148a-3p induced less than miR-148b-3p, yet the two miRNAs differed
only by the presence of “CU” at bases 9-10 in miR-148a-3p vs “UC” in miR-148b-3p. Interestingly it is the “U” at base 9 (present in miR-148b-3p and 148mut1, but not miR-148a-3p or
148mut2) that was linked to higher TNF- a induction (Fig 4.2A). We then treated wild-type or
TLR7 knock out macrophages with miR-148-a-3p, miR-148b-3p and their mutants (Fig 4.2A)
and similar pattern of TNF-a production was seen in wild-type macrophages.
The miR-20 family is more complex. We first examined the “U” at the 5’-end of miR-20a-5p,
since the other family members all contained a “C”. The change (20a-mut1) made no difference in the induction of TNF- a.
Subsequently, using site-directed nucleotide substitutions based on 20a-mut1 as well as
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using the natural family members, we found that the “U” at base 6 (20a-mut4), “C” at base 8
(20a-mut15), “U” at base 9 (20a-mut5), “U” at base 10 (miR-20b-5p), and “U” at base 12 (miR17-5p) were all important in inducing TNF- a production (Fig 3.10B). These mutants mostly
occurred as changes in the uridine residues within a “UGCUUAU” motif between bases 6 and
12, which has four “U”s out of the seven nucleotides, and, while the G was not essential, is 71%
“GU.” We also noted that miR-93-5p that contains a “GU” at bases 10-11 instead of “UA” (as
well as an A → C change at base 13) was still able to induce TNF-a. We saw similar pattern of
TNF-a production in wild-type macrophages, which confirms our findings in wild-type microglial cells (Fig 4.2B). Interestingly 20a-mut15 changes the “C” at base 8 to an “A” and this
change resulted in failure to induce cytokine production, without affecting GU content.
We also investigated the effects of GU-element for miR-29a-3p induced TNF-a production
in wild-type microglia. GU-rich sequence does not “guarantee” the production of TNF-a production, as shown in Figure 4.2 and Table 4.2. However, mutations of G or U components in
the “GGUUA” region of miR-29a-3p significantly diminished the TNF-a production.
Given the findings in this central region, we then undertook experiments using deletions
from the 5’- and 3’- end of 20a-mut1 (Fig 4.2C). While the first 4 bases from the 5’-end are dispensable, as exhibited by (-4)miR20a, deleting 4 more bases, (-8)miR20a, entering into the motif, eliminates TNF- a production. The last 8 bases at the 3’-end were also dispensable as seen
in miR20a(-8), even when combined with deletion of 4 bases from the 5’-end, as in (4)miR20a(-8). However, while removal of an additional base at from the 5’- or 3’-ends still resulted in TNF-a production in (-5)miR20a(-8) and (-4)miR20a(-9), removal of one addition base
from the 3’-end in (-4)miR20a(-10) eliminated cytokine production.
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Table 4.1.
miRNA

Sequence

G

U

A

C

G%

U%

A%

C%

miR-20a-5p

5'-UAAAGUGCUUAUAGUGCAGGUAG-3'

7

7

7

2

30%

30%

30%

9%

miR-20b-5p

5'-CAAAGUGCUCAUAGUGCAGGUAG-3'

7

5

7

4

30%

22%

30%

17%

miR-17-5p

5'-CAAAGUGCUUACAGUGCAGGUAG-3'

7

5

7

4

30%

22%

30%

17%

miR-93-5p

5'-CAAAGUGCUGUUCGUGCAGGUAG-3'

8

6

5

4

35%

26%

22%

17%

miR-148a-3p

5'-UCAGUGCACUACAGAACUUUGU-3'

4

7

6

5

18%

32%

27%

23%

miR-148b-3p

5'-UCAGUGCAUCACAGAACUUUGU-3'

4

7

6

5

18%

32%

27%

23%

Nucleotide composition analysis
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Figure 4.2
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Figure 4.2. Sequence-dependent stimulation of TLR7 in wild-type microglial cells.
The results are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0001 when compared
to standard (top condition in each). Nucleotides tested by mutagenesis indicated in bold in A
and B. Core motif underlined in C. (A) miR-148a-3p and miR-148b-3p and mutants; n=5 independent experiments for miR-148b-3p, n=3 for miR-148a-3p, n=4 for 148mut1 and 148mut2.
Treatment conditions as in Table 3.3 legend. (B): miR-20a-5p, miR-20b-5p, miR-93-5p, miR-175p and mutants; n=5 independent experiments for all except miR-20a-5p (n=6), 20a-mut1
(n=3), and 20a-mut15 (n=4). Treatment conditions as in Figure 1 legend. (C) 20a-mut1 and deletion mutants, n=3 independent experiments for all. For 20a-mut1 6 µg of RNA complexed to
DOTAP was used as in Figure 1 legend, for the deletion mutants the amount of RNA was adjusted to maintain equivalent molarity.
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Figure 4.3
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Figure 4.3. Sequence-dependent stimulation of TLR7 in wild-type macrophages.
The results are presented as mean ± SEM. *p < 0.05, **p < 0.01, when compared to standard
(top condition in each). Nucleotides tested by mutagenesis indicated in bold in A and B.
Treatment conditions as in Table 3.3 legend. (A) miR-148a-3p and miR-148b-3p and mutants;
n=4 independent experiments for all. (B): miR-20a-5p, miR-20b-5p, miR-93-5p, miR-17-5p and
mutants; n=3 independent experiments.
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Figure 4.4
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Figure 4.4. GU-dependent, miR-29a-3p induced stimulation of TLR7 in wild-type microglia.
The results are presented as mean ± SEM. **p < 0.01, ***p < 0001, when compared to standard (miR-29a-3p). Treatment conditions as in Table 3.3 legend. n=4 independent experiments
for all. Note: Actual sequences of miR-29a-3p, miR-29b-3p and their mutants shown in Table
3.6.
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Table 4.2.
Sequences of miR-29a-3p, miR-29b-3p and mutants

miRNA

Sequence

G%

U%

miR-29a-3p

5'-UAGCACCAUCUGAAAUCGGUUA-3'

27

18

miR-29b-3p

5'-UAGCACCAUUUGAAAUCAGUGUU-3'

35

17

29G mut

5'-UAGCACCAUCUGAAAUCAAUUA-3'

27

9

29Umut

5'-UAGCACCAUCUGAAAUCGGCCA-3'

18

18

29GU mut

5'-UAGCACCAUCUGAAAUCAACCA-3'

18

9
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4.2.3 PI3K, MAPK and NF-kB promote miRNA-stimulated transcription of proinflammatory molecules
We used various signaling inhibitors to test what pathway is involved in miRNA-EV mimicstimulated transcription of pro-inflammatory molecules. For this purpose, cells were incubated
with inhibitors for 30 minutes prior to stimulation with miR-20a-5p for 16 hrs. Total RNA was
isolated from the cells and cytokine mRNA levels were measured by quantitative RT-PCR. As
shown in Figure 3.13, the MLK-3 inhibitor URMC-099, PI3K inhibitor Wortmannin and IKK1/2
inhibitor BMS-345541 treatment of WT microglial cells was effective at inhibiting the miR-20a5p stimulated production of a number of pro-inflammatory cytokines including TNF-a, IL-1b,
IL-6, CCL5, and CXCL10 as well as the inflammatory enzyme cyclooxygenase-2 (PTSG-2) (Fig 4.5).
This observation indicates the essential requirements of PI3K, MAPK and NF-kB pathways in
promoting the miR-20a-5p induced transcription of pro-inflammatory molecules.
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Figure 4.5
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Figure 4.5. Effects of inhibitors of signal transduction pathways on miRNA-induced cytokine
production in cells.
WT mice microglial cells were incubated for 30 minutes with DMSO (vehicle), URMC-099 (100
nM), Wortmannin (1 µM) or BMS-345541 (10 µM), followed by miR-20a-5p : DOTAP treatment
as in the legend to Table 3.3. Cellular RNA was collected and assessed by qRT-PCR (using
GAPDH as a control housekeeping gene) for relative levels of the indicated mRNA. Data represent mean ± SEM. n = 3 independent experiments for all except for wortmannin treatment
where n=2.

91

4.2.4 miR-20a-5p, but not miR-20b-5p, causes peritoneal leukocyte migration in vivo
To examine the effectiveness of miRNAs with different sequences (based on prior results
indicating TLR7-dependent stimulation) in vivo, we injected miRNAs complexed to DOTAP
(miR-20a-5p and miR-20b-5p), as well as controls (DOTAP alone and saline) into the mouse
peritoneal space and harvested the peritoneal lavage 20 h later. Cells were gated for identification of myeloid cells as shown in Supplementary Figure 1. MiR-20a-5p injection in WT mice,
when compared with injection in TLR7ko mice, led to a significant increase in neutrophils (2.96
± 1.01 X 106 vs. 0.68 ± 0.54 X 106, p < 0.01) and monocytes (5.42 ± 1.74 X 106 vs. 1.37 ± 1.18 X
106, p < 0.05) (Figure 4.7&4.8). We also examined the two types of peritoneal macrophages,
large peritoneal macrophages (LPM), tissue resident macrophages that dominate by number in
the steady-state, and small peritoneal macrophages (SPM) which infiltrate due to inflammatory stimuli (125,126). While no change was found with LPM, we found that miR-20a-5p caused a
marked increase of SPM in WT mice compared with TLR7ko mice (5.15 ± 2.24 X 105 vs. 1.34 ±
0.77 X 105, p < 0.05) (Figure 4.8). MiR-20b-5p did not alter the number of any of these cells
between WT and TLR7ko mice. Therefore our data revealed that miR-20a-5p induced inflammatory leukocyte migration in vivo and further confirmed our in vitro finding that miR-20a-5p
could activate TLR7 via a specific sequence motif.
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Figure 4.6
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Figure 4.6. Gating strategy for peritoneal myeloid cells.
WT and TLR7ko mice were injected i.p. with 20 µg of miR-20a-5p, miR-20b-5p complexed with
DOTAP or DOTAP alone. After 20 hr, the peritoneal cells were harvested, stained, and analyzed.
Recovered cells (upper left) were first gated for live cells (live cells have low uptake of the dye,
whereas dead cells have higher uptake). Live cells were then subjected to a size gate, based on
forward (FSC) and side (SSC) scatter, and then doublets eliminated through examination of
height and area of the forward scatter (FSC-H and FSC-A). From the singlets, Neutrophils were
then identified as CD11b+Ly6G+, and from the non-neutrophils Monocytes identified as
CD11b+Ly6C+. LPMs were then identified from the remaining cells as CD11b+F4/80+, whereas
SPM had lower levels of both CD11b and F4/80.
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Figure 4.7 (A)
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Figure 4.7 (B)
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Figure 4.7. miR-20a-5p promotes peritoneal leukocyte recruitment in vivo.
The peritoneal lavage was harvested as described in Figure 4.7, and the peritoneal cells were
analyzed with flow cytometry. miR-20a-5p, but not miR-20b-5p, promotes NE (A) and Monocytes (B) migration into the peritoneal cavity.
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Figure 4.8
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Figure 4.8. MiR-20a-5p induced peritoneal leukocyte migration via TLR7 in vivo.
WT and TLR7ko mice were injected i.p. with 20 µg of miR-20a-5p, miR-20b-5p complexed with
DOTAP or DOTAP alone. After 20 hr, the peritoneal cells were harvested, stained, and analyzed.
The absolute number of neutrophils, monocytes, LPM and SPM, gated as in Figure 4.7. *p < 0.05,
**p < 0.01. n=5 independent experiments.
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4.3 Discussion
GU-rich sequences were identified in the original description of ssRNA sequences derived
from HIV-1 signaling through TLR7 (11) and supported in studies testing a range of sequences
(127). Other studies, resulting from the finding that influenza virus genomic RNA can signal
through TLR7, revealed that poly-U, but not poly-A, -C or -G could activate TLR7 (10). Sequence
specificity independent from GU-content was then found in studies of experimental small interfering RNA (siRNA) which were found to induce, rather than the expected suppression, of
interferon production in dendritic cells (128). This induction was found to be TLR7-dependent.
Interestingly in that study while a 19-nucleotide sequence containing the necessary 9nucleotide motif was highly stimulatory, reducing the length to 16 or 12 nucleotides (still containing the 9 bases) greatly reduced the response.
Indeed we found that the location of the specific nucleotides was critical (e.g. the CU vs UC
in miR-148a-3p vs miR-148b-3p). Furthermore, while the motif we found in miR-20a-5p
(UGCUUAU) was GU-rich, the Us as well as the C were critical for TLR7 activation. In addition,
we identified two short 10-nucleotide miRNA sequences, UGCUUAUAGU and GUGCUUAUAG,
containing this motif, that could strongly stimulate TNF-a production. These are the shortest
ssRNA sequences known to activate TLR7 described.
We speculate that within the innate immune system TLR7 can identify ssRNAs, including
miRNAs, as PAMPs through prevalence analysis of their sequence motifs and flanking context.
Certain motifs, such as our identified motif UGCUUAU present in miR-20a-5p, can lead to activation given that enough key flanking residues are also present. Therefore UGCUUAUAGU and
GUGCUUAUAG, but not GUGCUUAUA, could activate TLR7 signaling. In addition, our study
showed that within the naturally occurring miR-17-5p family (miR-20a-5p, miR-20b-5p, miR-
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17-5p, miR-93-5p) as well as the site-directed substitutions based on miR-20a-5p, some nucleotide substitutions within the core UGCUUAU motif still preserved signaling (e.g. UCCUUAU in
20a-mut9 and UGCUGUU in miR-93-5p), whereas others abrogated the TLR7-dependent signaling (e.g. CGCUUAU in 20a-mut4). These findings indicate that TLR7 recognizes miRNAs with
tolerance for certain amount of nucleotide substitutions within the core motif. Our results
with miR-135a/b-5p and miR-148a/b-3p pairs further emphasizes the sequence dependence.
Thus, TLR7 activation by miRNAs depends on both core sequence motifs and flanking context
of the miRNAs, and has tolerance for nucleotide substitutions within the motif of the miRNAs.
However, the nature of how this motif and context of miRNAs leads to TLR7 signaling remains unclear. Crystal structural study of rhesus monkey TLR7 and human TLR8 indicates that
both have two binding sites, a first site for small ligands and a second site for small ssRNA
(32,129). The imidazoquinolines Imiquimod (TLR7 only) and Resiquimod (TLR7 and TLR8), can
activate the receptors through binding the first site, whereas ssRNA stimulation requires both
sites to be occupied. Interestingly for TLR7, when crystalized with guanosine and poly-U 19mer, the structure revealed guanosine binding the first site, and shortened lengths of poly-U
(predominantly 4-mers) binding the second; additional experiments revealed that ssRNA binding to the second site increasing the affinity for guanosine at the first site (32). Crystallization
of TLR8 with two different ssRNAs revealed uridine at the first site and “UG” at the second site
(129). Interestingly again the intact ssRNAs were not detected, and these products had to result from ssRNA breakdown, even though purified recombinant molecules were used. The
same result occurred even when using phosphorothioated ssRNA. As these utilized recombinant proteins and added ligands, the actual mode of potential degradation of the ssRNA ligands and then binding to TLR7 or TLR8 have not been described. Furthermore, the structure of
mouse TLR7 has not been reported.
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The transcription of pro-inflammatory molecules after TLR7-dependent miR-20a-5p stimulation likely involves multiple signal transduction kinases as well as transcription factors. In our
study, we found that an inhibitor of IKK-1/2 (thus preventing IκBa phosphorylation and NF-kB
activation), PI3K, and MLK3 (thus inhibiting MAPKs) led to significantly attenuated transcription of cytokines expression following miRNA treatment. This is consistent with known modulators and effectors of TLR signaling.
Feng et al. reported that that TLR7 stimulating miRNAs were capable of leukocyte infiltration when injected into the peritoneal space (28). In our study, we found that miR-20a-5p induced migration of lymphocytes and monocytes when injected into the peritoneal space of
mice in a TLR7-specific fashion. We also found that the effects of miR-20a-5p were significantly
attenuated by the use of miR-20b-5p, which mutates the “UGCUUAU” motif to “UGCUCAU.”
Our in vivo data are consistent with our in vitro cytokine data and indicate that the miRNAinduced leukocyte migration is sequence and TLR7 dependent.
In addition, we identified marked different responses by the peritoneal monocyte/macrophage populations following miRNAs stimulation in vivo. Previous studies have defined two distinct subsets of peritoneal macrophages, SPMs and LPMs. Our findings demonstrated for the first time that SPMs and LPMs responded differently after miRNA stimulation in
vivo. Monocytes as well as SPMs, significantly increased after peritoneal miR-20a-5p administration in TLR7-expressing mice. LPMs, in contrast, did not response to miRNA stimulation.
We speculate that miRNAs stimulations can cause the influx of circulating inflammatory monocytes, which can differentiate into SPMs, into the peritoneal cavity via TLR7 activation.
In summary, we screened a wide profile of miRNAs inducing TNF-a response in multiple
cell lines, and identified a large number of miRNAs capable of inducing a TLR7-dependent in-
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flammatory response in microglia. We identified the unique “UGCUUAU” sequence motif of
miR-20a-5p that stimulates mouse TLR7 as well as the signaling transduction kinases that promote the miRNA-stimulated transcription of cytokines. In vivo, miR-20a-5p, but not miR-20b5p, is responsible for leukocyte migration and inflammation, depending on TLR7. Together, our
data suggest that extracellular miRNAs with specific sequence motif and length are potent
TLR7 activators and can trigger innate immune responses.
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Chapter 5. Conclusion
5.1 Overall conclusions and future directions
The work highlighted here investigates the miRNA-induced sequence-specific activation of
TLR7 both in vitro and in vivo. In the first chapter, we screened a wide profile of miRNAs for
their ability to induce TNF-a and IL-6 responses in macrophages and microglial cells through
TLR7. Indeed, many miRNAs can activate TLR7 in vitro and lead to pro-inflammatory mediator
production when present in EVs. We were puzzled by the relative lack of TNF-a production
following treatment with most of the let-7 family members (just low amounts with let-7a-5p,
higher levels only with let-7i-5p) in our experiments, despite attempting to replication conditions (with and without DOTAP, and the use of phosphorothiolate as well as phosphodiesterase linkages. It is still not clear the reason for this difference. However, the other previously
reported TLR7-activating miRNAs that were tested in detail (such as miR-21 and miR-29a), indeed activated microglia through TLR7 in our study.
In the following chapter by using closely related natural miRNA molecules, site-directed
and deletion mutants, we found a short 10-nucleotide sequence capable of stimulating TLR7.
This activity was dependent on a number of signaling pathways that characterize the TLR7 system. When given in vivo, administration of a miRNA-EV mimic could also induce leukocyte migration in a miRNA sequence-specific manner. The identification of sequence-specific miRNAs
activating TLR7 raises some interesting questions. According to the current results, the GUUG
motif for miR-21, GGUU for miR-29a, GUUGUGU for let-7b, UGCUUAU for miR-20a, UC for
miR-148b is essential for the miRNA-TLR7 recognition (13,25-27,36). However, other questions
remain. Can endosomal TLRs other than murine TLR7 be recognized by miRNAs? Can human
TLR7/TLR8 also be recognized sequence-specific miRNAs? It is previously reported that TLR8
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binds to uridine and the di-nucleotide UG (38). Analyses using purified TLR7 and TLR8 have
revealed that their binding to G or U requires preceding interaction between TLR7/8 with oligoribonucleotides. TLR7 and TLR8 respond to GU-rich and AU-rich ORNs (127). Future studies
using human TLR7 or TLR8, or investigate the possibility that other endosomal/lysosomal TLRs
or pattern recognition receptors might be activated by miRNAs may be warranted. We hypothesize that sequence-specific miRNAs will bind to endosomal TLRs and lead to production
of inflammatory cytokines.
TLR7 plays a vital role in the antiviral responses and the contact between a virus and uninfected TLR7-expressing cell is often sufficient to trigger the inflammatory cytokines and chemokines production without need for infection. Previous studies of the TLR7-dependent West
Nile virus, Human Respiratory Syncytial virus and Ross River virus responses have shown that
TLR7 represents a vital host defense mechanism against virus (130-132). The interactions of
TLR7 and miRNAs studied in our project mimics the virus-TLR7 interactions and provides new
insights for TLR7-associated antiviral therapies.
Our study also shows that EVs can be used as biomarkers for diagnostic purposes during
the progression of neurodegenerative diseases such as PD and AD. Currently in the bench settings, there are several methods of quantification of EVs. The number of particles can be
measured by Scattering/Fluorescent nanoparticle tracking analysis (optical detection of the
light/fluorescent light scattered or emitted by the particle), Resistive pulse sensing (measurement of the change in conductance across a sensing pore upon passage of a particle) and Flow
cytometry (optical detection of particles emitting fluorescent or scattered light). On the other
hand, the mass of EVs can be achieved by BCA or Surface plasmon resonance (measurement of
the change in refractive index upon absorption at a sensing interface). However, the time-
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consuming isolation procedures, the need for large sample volumes or the need for bulky instrumentation still limits the implementation of EVs as clinical biomarkers of neurodegenerative diseases. Current efforts are directed at the design of integrated devices allowing for the
detection and quantification of EVs in complex biofluid samples (133,134). Miniaturized microfluidic-based chips designed for both sample preparation (exosome purification (135), collection (136), lysis for RNA detection (137)) and detection (138,139) have been proposed and
hold promises for the rapid detection of EVs
The miRNA sensing endosomal/lysosomal TLRs, such as TLR7, are reported to be localized
in the ER and move to the endosomes or lysosomes upon stimulation. Future studies of the
mechanisms controlling TLR7 localization is critical to further our understanding of miRNATLR7 binding and downstream signaling. Moreover, in-depth analysis of the complex processes
regulating the localization and trafficking of TLR7 will provide new insights on fine-tuning immune responses in virus infection, cancer, and autoimmune diseases for the development of
novel therapeutics.
It is also worth noting that the free miRNAs without DOTAP complexation did not induce
TNF-a release in vitro, indicating miRNA mimics need to be enveloped in some type of carriers,
such as DOTAP, to protect them from degradation and/or enable them to efficiently reach the
endosome. Circulating miRNAs are also enveloped in some type of carriers, such as EVs. Our
study provides a physiological method of delivering miRNAs for potential therapeutic purposes.
TLR7 ligands are used pharmaceutically and experimentally for immune stimulation with applications to cancer, autoimmune and viral diseases, as well as vaccine efficacy (140-144). The
use of small ssRNA sequences, such as the 10-mer we identified, may be useful in certain formulations and conditions.
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